

STN Search (Registry/Caplus)

10/560,013

02/26/2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 OCT 23 The Derwent World Patents Index suite of databases on STN
has been enhanced and reloaded
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 6 NOV 10 CA/Caplus F-Term thesaurus enhanced
NEWS 7 NOV 10 STN Express with Discover! free maintenance release Version
8.01c now available
NEWS 8 NOV 20 CA/Caplus to MARPAT accession number crossover limit increased
to 50,000
NEWS 9 DEC 01 CAS REGISTRY updated with new ambiguity codes
NEWS 10 DEC 11 CAS REGISTRY chemical nomenclature enhanced
NEWS 11 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and
functionality
NEWS 13 DEC 18 CA/Caplus pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 14 DEC 18 CA/Caplus patent kind codes updated
NEWS 15 DEC 18 MARPAT to CA/Caplus accession number crossover limit increased
to 50,000
NEWS 16 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 17 DEC 27 CA/Caplus enhanced with more pre-1907 records
NEWS 18 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19 JAN 16 CA/Caplus Company Name Thesaurus enhanced and reloaded
NEWS 20 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 21 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22 JAN 22 CA/Caplus updated with revised CAS roles
NEWS 23 JAN 22 CA/Caplus enhanced with patent applications from India
NEWS 24 JAN 29 PHAR reloaded with new search and display fields
NEWS 25 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 26 FEB 13 CASREACT coverage to be extended
NEWS 27 Feb 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 28 Feb 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 29 Feb 23 KOREAPAT enhanced with IPC 8 features and functionality

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:28:25 ON 26 FEB 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:28:31 ON 26 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

DICTIONARY FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10560013\1.str




chain nodes :
 16 17
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11 12 13
 chain bonds :
 13-16 16-17
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 8-13 10-11 11-12 12-13
 exact/norm bonds :
 5-7 6-9 7-8 7-10 8-9 8-13 10-11 11-12 12-13 13-16 16-17
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

G1:NH,O,S

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 16:CLASS 17:Atom

L1 STRUCTURE UPLOADED

=> d
 L1 HAS NO ANSWERS
 L1 STR



G1 NH,O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
 FULL SEARCH INITIATED 12:28:47 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 809229 TO ITERATE

100.0% PROCESSED 809229 ITERATIONS (3 INCOMPLETE)
 SEARCH TIME: 00.00.07

253 ANSWERS

L2 253 SEA SSS FUL L1

=> fil caplus
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
172.10	172.31

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:29:04 ON 26 FEB 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Feb 2007 VOL 146 ISS 10
 FILE LAST UPDATED: 25 Feb 2007 (20070225/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

10/560,013

02/26/2007

=> s 12

L3 33 L2

=> d ibib abs hitstr 1-33


L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1207231 CAPLUS
 DOCUMENT NUMBER: 145:489114
 TITLE: Preparation of carbazoles and related compounds for treatment of dengue fever, yellow fever, west nile virus, and hepatitis C virus infection.
 INVENTOR(S): Gudmundsson, Kristjan
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 59pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006121467	A2	20061116	WO 2005-US41091	20051114
WO 2006121467	A3	20070125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, T2, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2004-630166P P 20041122


OTHER SOURCE(S): MARPAT 145:489114

GI




AB Title compds. [I; n = 0-2; X = NH, O, S, SO, SO₂; R, R₁ = halo, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aryloxy, arylamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, cyano, NO₂, N₃, etc.; P, q = 0-5; A = aryl, heteroaryl], were prepared for the treatment of infection due to flaviviruses, pestiviruses, and hepaciviruses. Thus, 6-chloro-N-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine (preparation outlined)


L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-16-4 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 812649-17-5 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 812649-18-6 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4-fluorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT showed anti-HCV activity with IC₅₀ = 5 nM.


812649-13-1P 812649-14-2P 812649-15-3P
 812649-16-4P 812649-17-5P 812649-18-6P
 812649-19-7P 812649-20-0P 812649-21-1P
 812649-22-2P 812649-23-3P 812649-24-4P
 812649-25-5P 812649-26-6P 812649-27-7P
 812649-28-8P 812649-29-9P 812649-30-2P
 812649-31-3P 812649-32-4P 812649-33-5P
 812649-34-6P 812649-35-7P 812649-36-8P
 812649-37-9P 812649-38-0P 812649-39-1P
 812649-41-5P 812649-42-6P 812649-44-8P
 812649-45-9P 812649-46-0P 812649-47-1P
 812649-48-2P 812649-49-3P 812649-50-6P
 812649-51-7P 812649-52-8P 812649-53-9P
 814255-17-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carbazoles and related compds. for treatment of dengue fever, yellow fever, west nile virus, and hepatitis C virus infection)


RN 812649-13-1 CAPLUS

CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)



RN 812649-14-2 CAPLUS

CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 812649-15-3 CAPLUS


CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-19-7 CAPLUS

CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 812649-20-0 CAPLUS

CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 812649-21-1 CAPLUS

L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI)
 (CA INDEX NAME)




RN 812649-22-2 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
 (CA INDEX NAME)




RN 812649-23-3 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethoxy-2-pyrimidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 812649-27-7 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-28-8 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4,6-dimethyl-2-pyrimidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 812649-29-9 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(5-propyl-2-pyrimidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 812649-24-4 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-25-5 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-26-6 CAPLUS


L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)



RN 812649-30-2 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methyl-N-2-pyrimidinyl- (9CI)
 (CA INDEX NAME)




RN 812649-31-3 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methoxy-N-2-pyrimidinyl- (9CI)
 (CA INDEX NAME)




RN 812649-32-4 CAPLUS
 CN 1H-Carbazol-1-amine, N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 812649-33-5 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 812649-34-6 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 812649-37-9 CAPLUS
 CN 1H-Carbazol-1-amine, N-2-benzothiazolyl-6-bromo-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 812649-38-0 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 812649-39-1 CAPLUS
 CN Cyclohept[b]indol-6-amine, 2-bromo-5,6,7,8,9,10-hexahydro-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 812649-41-5 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methyl-N-2-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-35-7 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 812649-36-8 CAPLUS
 CN 3-Pyridinecarbonitrile, 6-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 812649-42-6 CAPLUS
 CN 1H-Carbazole-6-carboxylic acid, 2,3,4,9-tetrahydro-1-(phenylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 812649-44-8 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl-6-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 812649-45-9 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-46-0 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(3-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 812649-47-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 812649-48-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-1H-indol-5-yl- (9CI)
(CA INDEX NAME)


L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-49-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(2-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 812649-50-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 812649-51-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)


L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-52-8 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 812649-53-9 CAPLUS
CN 1H-Carbazole, 6-bromo-1-(4-fluorophenoxy)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)



RN 814255-17-9 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)amino]- (9CI)
(CA INDEX NAME)

L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L3 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1207230 CAPLUS
 DOCUMENT NUMBER: 145:500040
 TITLE: Treatment or prophylaxis of Flaviviridae viruses
 using substituted 2,3,4,9-tetrahydro-1H-carbazoles and related compounds
 INVENTOR(S): Gudmundsson, Kristjan
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 70pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006121466	A2	20061116	WO 2005-US41090	20051114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.: US 2004-629906P P 20041122

OTHER SOURCE(S): MARIAT 145:500040
 GI



AB The present invention relates to 2,3,4,9-tetrahydro-1H-carbazoles and related compds. (shown as I; variables defined below; e.g. N-benzyl-2,3,4,9-tetrahydrocarbazol-1-amine hydrochloride) that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compds. useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV. For I: n = 0-2; R is H or alkyl; X is NR2, O, or S(O)m; each R1 = H, halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, Ay, -NHR10Ay, Het, -R10NR2R3, -R10NR2R3, -OR2, -OAY, -OHet, -R10OR2, -NR2R3, -NR2Ay, -R10NR2R3, et al.; Y is (un)substituted alkylene, cycloalkylene, alkenylene, cycloalkenylene, or alkynylene; d = 0-1; Z is -R2, -OR2, -C(O)R2, -C(O)2R2, -S(O)mR2, -C(O)NR2R3, -Het, or Ay, provided when d is 0, then Z is not -Het or -Ay; each m = 0-2; each R10 = alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene; p = 0-4; each of R2 and R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, -R10OH, -R10(OR10)w, and -R10NR5R6; w = 1-10; each of R5 and R6 = alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl; Ay = (un)substituted


L3 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 -NHHet, -NHR10Het, -OR2, -OAY, -OHet, -R10OR2, -NR2R3, -NR2Ay, -R10NR2R3, et al.; Y is (un)substituted alkylene, cycloalkylene, alkenylene, cycloalkenylene, or alkynylene; d = 0-1; Z is -R2, -OR2, -C(O)R2, -C(O)2R2, -S(O)mR2, -C(O)NR2R3, -Het, or Ay, provided when d is 0, then Z is not -Het or -Ay; each m = 0-2; each R10 = alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene; p = 0-4; each of R2 and R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, -R10OH, -R10(OR10)w, and -R10NR5R6; w = 1-10; each of R5 and R6 = alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl; Ay = (un)substituted
 aryl:
 Het = (un)substituted 5- or 6-membered heterocyclyl or heteroaryl group; addnl. details are given in the claims. Inhibition of HCV activity was measure for 3 examples of I, e.g. IC50 = 8 nM for (1R)-6-Bromo-N-((1S)-1-phenylethyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride. Although the methods of prep. are not claimed, preps. and/or characterization data for, approx. 70 examples of I are included. For example, N-benzyl-2,3,4,9-tetrahydrocarbazol-1-amine hydrochloride was prep. (35 % yield) by addn. of sodium triacetoxymethylborohydride, acetic acid and benzylamine to a dichloroethane soln. of 2,3,4,9-tetrahydro-1H-carbazol-1-one, which was prep. in 2 steps from 4-chloroaniline, NaNO2 and 2-(hydroxymethylene)cyclohexanone in which the intermediate cyclohexane-1,2-dione (4-chlorophenyl)hydrazone was cyclized.
 IT 847988-07-2, 6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process) (chromatog. resolution; treatment or prophylaxis of Flaviviridae viruses using substituted 2,3,4,9-tetrahydro-1H-carbazoles and related compds.)
 RN 847988-07-2 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



IT 847988-06-1P, (1R)-6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride 847988-08-3P,
 (1S)-6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

L3 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PREP (Preparation); USES (Uses)
 (drug candidate; treatment or prophylaxis of Flaviviridae viruses using substituted 2,3,4,9-tetrahydro-1H-carbazoles and related compds.)
 RN 847988-06-1 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 847988-08-3 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


IT 847987-99-9P, N-Cyclohexyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride 847988-00-5P, N-(2,3-Dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride 847988-24-3P, N-(2,3-Dihydro-1H-inden-2-yl)-6-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride 847988-48-1P, 7-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L3 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (Uses)
 (drug candidate; treatment or prophylaxis of Flaviviridae viruses using substituted 2,3,4,9-tetrahydro-1H-carbazoles and related compds.)
 RN 847987-99-9 CAPLUS
 CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 847988-00-5 CAPLUS
 CN 1H-Carbazol-1-amine, N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 847988-24-3 CAPLUS
 CN 1H-Carbazol-1-amine, N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 847988-48-1 CAPLUS
 CN 1H-Carbazol-1-amine, 7-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L3 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:797404 CAPLUS
 DOCUMENT NUMBER: 145:397203
 TITLE: Intermolecular [4 + 2] Cycloaddition of o-Quinodimethanes Derived from Ene-Bis(sulfinylallenes)
 AUTHOR(S): Kitagaki, Shinji; Katoh, Kumiko; Ohdachi, Kazuhiro; Takahashi, Yuji; Shibata, Daisuke; Mukai, Chisato
 CORPORATE SOURCE: Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan
 SOURCE: Journal of Organic Chemistry (2006), 71(18),
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Intermol. [4 + 2] cycloaddn. of o-quinodimethanes, prepared in situ from ene-bis(propargylalcs.) and benzenesulfonyl chloride via ene-bis(sulfinylallene) formation, was investigated. Benzene-bridged bis(propargyl alcs.) reacted with both electron-deficient and electron-rich olefins to give the corresponding [4 + 2] cycloadducts. E.g., reaction of ene-bis(propargyl alc.) I with benzenesulfonyl chloride and di-Me fumarate, followed by oxidation with mCPBA, gave up to 84% cycloadduct II. Ethylene-bridged bis(propargyl alcs.) underwent similar cycloaddn. with electron-deficient olefins. Construction of some heterocycles based on the newly developed sequential reaction is also described.
 IT 911710-49-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Intermol. [4 + 2] cycloaddn. of dienophiles with o-quinodimethanes prepared in situ from ene-bis(propargyl alcs.) and benzenesulfonyl chloride via ene-bis(sulfinylallene) formation)
 RN 911710-49-1 CAPLUS
 CN 5H-Benzo[b]carbazole-8,9-dicarboxylic acid, 7,8,9,10-tetrahydro-6,11-bis(phenylsulfonyl)-, dimethyl ester, (8R,9R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L3 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:697809 CAPLUS
 DOCUMENT NUMBER: 145:314757
 TITLE: Photo-Fries rearrangement of carbazol-2-yl sulfonates:
 efficient tool for the introduction of sulfonyl
 groups
 into polycyclic aromatic compounds
 AUTHOR(S): Crevatin, Laura K.; Bonesi, Sergio M.; Erra-Balsells, Rosa
 CORPORATE SOURCE: CIHIDECAR-CONICET, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, 1428, Argent.
 SOURCE: Helvetica Chimica Acta (2006), 89(6), 1147-1157
 CODEN: HCACAV; ISSN: 0018-019X
 PUBLISHER: Verlag Helvetica Chimica Acta
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Systematic studies on the photo-Fries rearrangement of different 9H-carbazolyl sulfonates have shown that this type of conversion can be readily used for the preparative-scale introduction of alkyl- or arylsulfonyl groups into polycyclic aromatic compds. under very mild conditions. A series of new 1-sulfonyl- or 3-sulfonyl-9H-carbazole derivs. were prepared in medium-to-good yields, and characterized by UV/VIS, 1H-NMR, and 13C-NMR spectroscopy, as well as by elemental anal. Effects of irradiation wavelength, solvent polarity, presence or absence of O2, and photosensitizers were studied in detail. For example, the rearrangement of -9H-carbazol-2-ol methanesulfonate (ester) gave 1-(methylsulfonyl)-9H-carbazol-2-ol (major product) and 3-(methylsulfonyl)-9H-carbazol-2-ol.
 IT 908850-23-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of (sulfonyl)carbazolol derivs. via regioselective photo-Fries rearrangement of carbazolol sulfonate esters)
 RN 908850-23-7 CAPLUS
 CN 9H-Carbazol-2-ol, 1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:608619 CAPLUS
 DOCUMENT NUMBER: 145:83213
 TITLE: Preparation of tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
 INVENTOR(S): Lennox, William Joseph; Qi, Hongyan; Lee, Duck-Hyung; Choi, Soongyu; Moon, Young-Choon
 PATENT ASSIGNEE(S): PTC Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 137 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006065480	A2	20060622	WO 2005-US42483	20051123
WO 2006065480	A3	20060803		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-629889P P 20041123
 US 2004-633738P P 20041206
 US 2004-639283P P 20041227

OTHER SOURCE(S): MARPAT 145:83213
 GI

L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The present invention relates to methods, compds., and compns. for inhibiting angiogenesis. More particularly, the present invention relates to methods, compds., and compns. for inhibiting VEGF production. The title compds. I (X = NR9R10, N(alkyl)C(O)aryl, H, etc. (wherein R9, R10 = H, alkyl, aryl, etc.; or NR9R10 = mono- or bicyclic heterocyclic ring); R1-R3 = H, OH, alkyl (wherein R1 may optionally form (un)substituted 5-11 membered mono- or bi-heterocyclic ring with X); n = 0-2; R4-R7 = H, OH, alkyl, etc.; W = N, O, S; R8 = H, alkyl, cycloalkyl, etc.; with the provision) were prepared. Thus, reacting amine II with 2,3-diformylthiophene followed by treating the intermediate lactam III with LAH in THF afforded IV which showed EC50 of <0.01 μ M in an assay evaluating the ability of compds. I to modulate hypoxia-inducible endogenous VEGF expression.

IT 812649-13-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Preparation of tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control)


RN 812649-13-1 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 812649-16-4P 812649-17-5P 812649-20-0P
 812649-21-1P 812649-22-2P 812649-46-0P
 812649-47-1P 812649-49-3P 812649-50-6P
 812649-51-7P 812649-52-8P 812649-53-9P
 812655-12-4P 812655-18-0P 893409-63-7P
 893409-67-1P 893409-69-3P 893409-71-7P
 893409-75-1P 893409-76-2P 893409-77-3P
 893409-79-5P 893409-82-0P 893409-83-1P
 893409-85-3P 893409-86-4P 893409-87-5P
 893409-88-6P 893409-93-3P 893409-96-6P
 893409-97-7P 893409-99-9P 893410-02-1P
 893410-06-5P 893410-08-7P 893410-10-1P
 893410-32-7P 893410-61-2P 893410-62-3P
 893410-63-4P 893410-64-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control)

RN 812649-16-4 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 812649-17-5 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-20-0 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 812649-21-1 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-22-2 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)


L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)




RN 812649-46-0 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(3-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 812649-47-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 812649-52-8 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 812649-53-9 CAPLUS
CN 1H-Carbazole, 6-bromo-1-(4-fluorophenoxy)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 814255-12-4 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-2-pyrimidinyl- (9CI)
(CA INDEX NAME)




RN 814255-18-0 CAPLUS


L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 812649-49-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(2-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 812649-50-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 812649-51-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 893409-63-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 893409-67-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 893409-69-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-phenoxypheyl)- (9CI)
(CA INDEX NAME)


L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893409-71-7 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 893409-75-1 CAPLUS
CN 1H-Carbazol-1-amine, N-1,3-benzodioxol-5-yl-6-bromo-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 893409-76-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893409-83-1 CAPLUS
CN 1H-Carbazol-1-amine, N-[1,1'-biphenyl]-4-yl-6-bromo-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 893409-85-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-pyrazinyl- (9CI) (CA INDEX NAME)




RN 893409-86-4 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-difluorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893409-77-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3-chlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 893409-79-5 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3,5-dimethylphenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 893409-82-0 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-phenylcyclohexyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893409-87-5 CAPLUS
CN Cyclohept[b]indol-6-amine, 2-bromo-5,6,7,8,9,10-hexahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 893409-88-6 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl-6-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 893409-93-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 893409-96-6 CAPLUS
CN 1H-Carbazol-1-amine, 5-bromo-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 893409-97-7 CAPLUS
CN Benzonitrile, 4-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]- (9CI) (CA INDEX NAME)




L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893410-10-1 CAPLUS
CN Benzeneethanol, 3-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]- (9CI) (CA INDEX NAME)




RN 893410-32-7 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-1H-pyrrol-1-yl- (9CI) (CA INDEX NAME)




RN 893410-61-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 893409-99-9 CAPLUS
CN 1H-Carbazol-1-amine, 7-bromo-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)



RN 893410-02-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-3-isoxazolyl- (9CI) (CA INDEX NAME)




RN 893410-06-5 CAPLUS
CN Acetamide, N-[4-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 893410-08-7 CAPLUS
CN 1,4-Benzenediamine, N'-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N,N-


L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893410-62-3 CAPLUS
CN 1H-Carbazol-1-amine, N-(4-chlorophenyl)-2,3,4,9-tetrahydro-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 893410-63-4 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-(4-methoxyphenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 893410-64-5 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 118498-97-8 471259-01-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control)
 RN 118498-97-8 CAPLUS
 CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-methyl- (9CI) (CA INDEX NAME)



RN 471259-01-5 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-nitro-N-(4-phenylcyclohexyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L3 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:404930 CAPLUS
 DOCUMENT NUMBER: 145:465904
 TITLE: Reactions of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK) with the ABTS cation radical: identification of new oxidation products
 AUTHOR(S): Than, N1 Ni; Heer, Christina; Laatsch, Hartmut; Hardeland, Ruediger
 CORPORATE SOURCE: Institutes of Organic and Biomolecular Chemistry, University of Goettingen, Goettingen, Germany
 SOURCE: Redox Report (2006), 11(1), 15-24
 CODEN: RDRPE4; ISSN: 1351-0002
 URL: <http://www.ingentaconnect.com/content/maney/rer/2>
 PUBLISHER: 006/00000011/00000001
 DOCUMENT TYPE: Maney Publishing
 LANGUAGE: Journal; (online computer file)
 AB The melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK; 1), which was previously shown to be a potent radical scavenger, was oxidized using the ABTS cation radical [ABTS = 2,2'-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid)]. Several new oxidation products were obtained, which were separated by repeated chromatog. and characterized by spectroscopic methods such as mass spectrometry (ESI-MS and ESI-HRMS), 1H-NMR and 13C-NMR, HMQC, H,H COSY correlations and IR spectroscopy. The main products were oligomers of 1 (3 dimers, 1 trimer and 2 tetramers). In all cases, the amino group N2 was involved in the reactions. Two of the dimers turned out to be cis (2a) and trans (2b) isomers containing an azo bond. In the other dimer (3a), the nitrogen atom N2 was attached to atom C5 of the second aromatic amine, with loss of the methoxy group. In the trimer, one N2 formed a bridge to C5 of unit B, as in the resp. dimer, while this one of C had bridged to C6 of B. One of the tetramers was composed of a trimer 5 attached to N2 of a fourth 1 mol. via an azo bond as in 2a/b. In the other tetramer, an addnl. C-C bond between rings B and C in 6 is assumed. Although oligomers of AMK may only attain low in vivo concns., the types of reactions observed shed light on the physiol. possible metabolism of AMK once reacted with a free radical. The displacement of a methoxy group, rarely seen in the oxidation of methoxylated biomols., underlines the reactivity of AMK. Preliminary data show that, in the presence of ABTS cation radicals, AMK can interact with side chains of aromatic amino acids, a finding which may be crucial for understanding to date unidentified protein modification by a melatonin metabolite detected earlier in expts. with radioactively labeled melatonin.


IT 914087-91-5
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (reactions of melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK) with ABTS cation radical and identification of new oxidation products)
 RN 914087-91-5 CAPLUS
 CN Acetamide, N,N'-[[8-[[2-[3-(acetylamino)-1-oxopropyl]-4-

L3 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methoxyphenyl]amino)-5-[[2-[3-(acetylamino)-1-oxopropyl]-4-methoxyphenyl]azo]-3-methoxy-9H-carbazole-1,6-diyl]bis(3-oxo-3,1-propanediyl)]bis- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:128535 CAPLUS
 DOCUMENT NUMBER: 144:369846
 TITLE: Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists
 AUTHOR(S): Di Fabio, Romano; Giovannini, Riccardo; Bertani, Barbara; Borriello, Manuela; Bozzoli, Andrea; Donati, Daniele; Falchi, Alessandro; Ghirlanda, Damiano; Leslie, Colin P.; Pecunioso, Angelo; Rumboldt, Giovanna; Spada, Simone
 CORPORATE SOURCE: GlaxoSmithKline Medicines Research Centre, Verona, 37135, Italy
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1749-1752
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:369846
 GI




AB The SAR of a new series of tetrahydrocarbazole derivs. I [R1 = Me, 3-(1-piperidinyl)propyl, piperidin-4-ylmethyl, etc.; R2 = H, 4-morpholinyl, 1-piperidinyl, 4-methyl-1-piperazinyl, etc.] is evaluated: the appropriate decoration of this template led to the identification of a new class of NPY-1 antagonists showing good in vitro potency and a promising in vivo pharmacokinetic profile in rat.
 IT 882033-76-3P 882033-77-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and SAR of amino(chlorophenoxy)tetrahydrocarbazolones as NPY-1 antagonists)
 RN 882033-76-3 CAPLUS
 CN 1H-Carbazole, 1-(4-chlorophenoxy)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 882033-77-4 CAPLUS
 CN 4H-Carbazol-4-one, 1-(4-chlorophenoxy)-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:444285 CAPLUS
 DOCUMENT NUMBER: 143:162008
 TITLE: Effects of fluorination on electronic and excited states of fused zinc oligoporphyrins
 AUTHOR(S): Yamaguchi, Yoichi
 CORPORATE SOURCE: KRI, Kyoto, 600-8813, Japan
 SOURCE: Journal of Chemical Physics (2005), 122(18), 184702/1-184702/10
 CODEN: JCPSA6; ISSN: 0021-9606
 PUBLISHER: American Institute of Physics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB D. functional theory (DFT) has been applied to study the effect of fluorination on the electronic and excited states of fused zinc oligoporphyrins in the search for new functionalizing materials, such as n-type organic semiconductors. The excitation spectra of meso-tetrafluoro, β-octafluoro, and perfluoro zinc porphyrins, and their triply meso-meso-, β-β-, and β-β-linked fluorinated zinc oligoporphyrins were systematically examined using the time-dependent DFT method. The effect of the perfluorination on the zinc porphyrin (ZnP) causes the maximum 1.12 eV and 1.42 eV drops for the highest occupied and LUMO (HOMO and LUMO, resp.) levels, resp. The electronic and excitation features of the fluorinated ZnPs are almost similar to the unfluorinated ones. However, the large antibonding contribution of the meso-fluorines disturbs the stabilization of the HOMO, resulting in a more effective reduction of both the HOMO-LUMO gaps and the lowest Q excitation energies with the increasing number of porphyrins compared to the unfluorination and the other types of fluorinations. It is found that the infinite fused fluorinated ZnP tapes with narrow gap (=0.1 eV-0.2 eV) as predicted by using the periodic-DFT level are slightly inferior to the near-zero gap semimetallic unfluorinated ZnP tape as a conducting mol. wire. The combination of the condensation and the meso- and/or β-fluorination of ZnP can finely tune the LUMO level to the Fermi level of the electrodes for fabrication of n-type conducting materials. The fused fluoro-oligoporphyrins may then become new n-type organic semiconductors, provided they are well crystallized with a high electron mobility, such as the recently synthesized perfluoropentacene.
 IT 859507-60-1
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
 (comparison; fluorination effect on electronic and excited states of fused zinc oligoporphyrins in relation to)
 RN 859507-60-1 CAPLUS
 CN Poly(5,15-difluoro-21H,23H-porphine-2,18,20:8,10,12-hexayl- κ N1, κ N22, κ N23, κ N24 (SP-4-1)-zinc complex) (9CI) (CA INDEX NAME)


L3 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:371222 CAPLUS
 DOCUMENT NUMBER: 142:430133
 TITLE: Preparation of carbazoles and related compounds as antiviral agents
 INVENTOR(S): Ni, Zhi-Jie; Chang, Bryan; Wang, Weibo; Weiner, Amy
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037791	A1	20050428	WO 2004-US34169	20041015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1678137	A1	20060712	EP 2004-795347	20041015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.: US 2003-511769P P 20031015				
WO 2004-US34169 W 20041015				
OTHER SOURCE(S): MARPAT 142:430133				
GI				




AB Title compds. I [R1 = H, halo, formyl, etc.; R2 = heteroaryl, arylalkyl, alkyl, etc.; R7 = H, NH2, alkyl, etc.; R9 = H, alkyl; n = 1-4; p = 0-2] and their pharmaceutically acceptable salts were prepared. For example, reductive amination of 6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-one, e.g.,

L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 prepd. from 4-bromoaniline, with cyclohexylamine afforded 6-bromo-N-cyclohexyl-2,3,4,9-tetrahydro-1H-carbazole-1-amine (II). In


HCV inhibition assays, compd. II-CF3CO2H showed activity at <4 µM. Comps. I are claimed useful for the treatment of HCV, SARS, etc.
 IT 118498-97-8P 419576-59-3P 471259-03-7P
 851054-01-8P 851054-02-9P 851054-03-0P
 851054-04-1P 851054-08-5P 851054-13-2P
 851054-18-7P 851054-28-9P 851054-29-0P
 851054-30-3P 851054-39-2P 851054-41-6P
 851054-42-7P 851054-46-1P 851054-47-2P
 851054-48-3P 851054-49-4P 851054-50-7P
 851054-53-0P 851054-55-2P 851054-56-3P
 851054-57-4P 851054-59-6P 851054-66-5P
 851054-67-6P 851054-71-2P 851054-75-6P
 851054-84-7P 851054-86-9P 851054-87-0P
 851054-88-1P 851054-92-7P 851054-93-8P
 851054-94-9P 851054-96-1P 851054-97-2P
 851054-98-3P 851054-99-4P 851055-00-0P
 851055-01-1P 851055-05-5P 851055-06-6P
 851055-07-7P 851055-08-8P 851055-10-2P
 851055-11-3P 851055-12-4P 851055-13-5P
 851055-14-6P 851055-15-7P 851055-16-8P
 851055-17-9P 851055-18-0P 851055-21-5P
 851055-22-6P 851055-23-7P 851055-27-1P
 851055-31-7P 851055-32-8P 851055-33-9P
 851055-34-0P 851055-37-3P 851055-38-4P
 851055-41-9P 851055-50-0P 851055-51-1P
 851055-54-4P 851055-55-5P 851055-63-5P
 851055-70-4P 851055-75-9P 851055-79-3P
 851055-80-6P 851055-88-4P 851055-91-9P
 851055-98-6P 851056-00-3P 851056-01-4P
 851056-02-5P 851056-03-6P 851056-04-7P
 851056-05-8P 851056-06-9P 851056-10-5P
 851056-14-9P 851056-15-0P 851056-16-1P
 851056-17-2P 851056-18-3P 851056-19-4P
 851056-20-7P 851056-21-8P 851056-22-9P
 851056-23-0P 851056-24-1P 851056-25-2P
 851056-26-3P 851056-27-4P 851056-28-5P
 851056-29-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of carbazoles and related compds. as antiviral agents for treatment of HCV, SARS, etc.)
 RN 118498-97-8 CAPLUS
 CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 419576-59-3 CAPLUS
 CN 1H-Carbazol-1-amine, N-(1-ethyl-4-piperidinyl)-2,3,4,9-tetrahydro-6-nitro- (9CI) (CA INDEX NAME)




RN 471259-03-7 CAPLUS
 CN 1H-Carbazol-1-amine, N-bicyclo[2.2.1]hept-2-yl-2,3,4,9-tetrahydro-6-nitro- (9CI) (CA INDEX NAME)



RN 851054-01-8 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-cyclohexyl-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-02-9 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-cyclohexyl-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

CM 1

CRN 851054-01-8
 CHF C18 H23 Br N2




CM 2

CRN 76-05-1
 CHF C2 H F3 O2



RN 851054-03-0 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-cyclohexyl-2,3,4,9-tetrahydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-04-1 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 851054-03-0
CMF C26 H31 N3 O




CM 2


CRN 76-05-1
CMF C2 H F3 O2




L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-methyl- (9CI) (CA INDEX NAME)



RN 851054-29-0 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-methyl- (9CI) (CA INDEX NAME)




RN 851054-30-3 CAPLUS
CN 1H-Carbazole-6-carboxylic acid, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)




RN 851054-39-2 CAPLUS


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 851054-08-5 CAPLUS
CN 1H-Carbazol-1-amine, N-cyclohexyl-6-fluoro-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 851054-13-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-N-cyclohexyl-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851054-18-7 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-methyl- (9CI) (CA INDEX NAME)




RN 851054-28-9 CAPLUS


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 851054-41-6 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-N-ethyl-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851054-42-7 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 851054-46-1 CAPLUS
CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-47-2 CAPLUS
CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 851054-48-3 CAPLUS
CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 851054-49-4 CAPLUS
CN 1H-Carbazol-1-amine, 7-bromo-N-cyclohexyl-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-56-3 CAPLUS
CN 1H-Carbazol-6-carboxamide, N-ethyl-2,3,4,9-tetrahydro-1-[(4-methylcyclohexyl)amino]- (9CI) (CA INDEX NAME)




RN 851054-57-4 CAPLUS
CN 1H-Carbazol-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 851054-59-6 CAPLUS


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-50-7 CAPLUS
CN 1H-Carbazol-1-amine, 8-bromo-N-cyclohexyl-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851054-53-0 CAPLUS
CN 1H-Carbazol-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 851054-55-2 CAPLUS
CN 1H-Carbazol-6-carboxamide, 1-(cycloheptylamino)-N-ethyl-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Carbazol-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 851054-66-5 CAPLUS
CN Cyclobutanecarboxamide, N-[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]- (9CI) (CA INDEX NAME)




RN 851054-67-6 CAPLUS
CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 851054-71-2 CAPLUS
CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-75-6 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 851054-84-7 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-N-(2-furanylmethyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851054-86-9 CAPLUS
CN Cyclopentanecarboxamide, N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl)]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-93-8 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 851054-94-9 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 851054-96-1 CAPLUS
CN 1H-Carbazole-6-carboxamide, N-cyclohexyl-1-(cyclohexylamino)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-87-0 CAPLUS
CN 1H-Carbazole-6-methanamine, N-cyclohexyl-1-(cyclohexylamino)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851054-88-1 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-[(2,3,4,9-tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 851054-92-7 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-97-2 CAPLUS
CN Cyclopentanecarboxamide, N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl)]- (9CI) (CA INDEX NAME)




RN 851054-98-3 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-N-(cyclohexylmethyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851054-99-4 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-[(2R)-2-furanylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 851055-00-0 CAPLUS
 CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 851055-01-1 CAPLUS
 CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-[(2S)-tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 851055-10-2 CAPLUS
 CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-N-[(4-fluorophenyl)methyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851055-11-3 CAPLUS
 CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 851055-12-4 CAPLUS
 CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-N-(cyclohexylmethyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 851055-05-5 CAPLUS
 CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 851055-06-6 CAPLUS
 CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 851055-07-7 CAPLUS
 CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 851055-08-8 CAPLUS


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-13-5 CAPLUS
 CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(2-(1-pyrrolidinylethyl)- (9CI) (CA INDEX NAME)




RN 851055-14-6 CAPLUS
 CN Benzenamide, N-[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 851055-15-7 CAPLUS
 CN Benzenepropanamide, N-[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-16-8 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 851055-17-9 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 851055-18-0 CAPLUS
CN 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-1-[(4-methylcyclohexyl)amino]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-27-1 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 851055-31-7 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 851055-32-8 CAPLUS
CN Benzeneacetamide, N-[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-21-5 CAPLUS
CN Benzeneacetamide, N-[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 851055-22-6 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-N-[2-(4-fluorophenyl)ethyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851055-23-7 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(2-(1-(4-fluorophenyl)ethyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-33-9 CAPLUS
CN Benzenebutanamide, N-[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]- (9CI) (CA INDEX NAME)




RN 851055-34-0 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)




RN 851055-37-3 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-38-4 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-N-[2-(4-fluorophenyl)ethyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851055-41-9 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 851055-50-0 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-N-[[4-(dimethylamino)phenyl]methyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 851055-63-5 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-N-[[4-(trifluoromethyl)phenyl]methyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851055-70-4 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-N-[2-[2-[[5-((3aR, 4R, 6aS)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]ethoxy]ethoxy]ethyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-51-1 CAPLUS
CN Benzamide, N-[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-2,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 851055-54-4 CAPLUS
CN Benzamide, N-[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 851055-55-5 CAPLUS
CN 1H-Carbazole-6-methanamine, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 851055-75-9 CAPLUS
CN Cyclopent[b]indol-3-amine, N-cyclohexyl-1,2,3,4-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)




RN 851055-79-3 CAPLUS
CN 1H-Carbazole-6-carboxylic acid, 1-(cyclohexylamino)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851055-80-6 CAPLUS
CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-phenyl- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-88-4 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 851055-91-9 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cycloheptylamino)-2,3,4,9-tetrahydro-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 851055-98-6 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclopentylamino)-N-ethyl-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 851056-02-5 CAPLUS
CN Piperazine, 1-[[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 851056-03-6 CAPLUS
CN Piperidine, 1-[[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 851056-04-7 CAPLUS
CN Pyrrolidine, 1-[[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 851056-05-8 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-N-ethyl-2,3,4,9-tetrahydro-N-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 851056-00-3 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-N-[2-(dimethylamino)ethyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 851056-01-4 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-N-[3-(4-morpholinyl)propyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851056-06-9 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclopentylamino)-N-ethyl-2,3,4,9-tetrahydro-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 851056-10-5 CAPLUS
CN Morpholine, 4-[[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 851056-14-9 CAPLUS
CN Cyclopropanecarboxamide, N-(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl)- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851056-15-0 CAPLUS
CN Propanamide,
N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl)-2-
methyl]- (9CI) (CA INDEX NAME)




RN 851056-16-1 CAPLUS
CN Benzamide, N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl)-2-
fluoro]- (9CI) (CA INDEX NAME)




RN 851056-17-2 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-
carbazol-6-yl)-2-fluoro]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851056-21-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-
carbazol-6-yl)-2-fluoro]- (9CI) (CA INDEX NAME)




RN 851056-22-9 CAPLUS
CN 1H-Carbazol-6-methanamine,
N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl)-2-
methyl]- (9CI) (CA INDEX NAME)




RN 851056-23-0 CAPLUS
CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-(1-
pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851056-18-3 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-
carbazol-6-yl)-2-methyl]- (9CI) (CA INDEX NAME)




RN 851056-19-4 CAPLUS
CN [1,1'-Biphenyl]-4-acetamide,
N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl)-2-
methyl]- (9CI) (CA INDEX NAME)




RN 851056-20-7 CAPLUS
CN Butanamide, N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl)-2-
methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851056-24-1 CAPLUS
CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-[(4-methyl-1-
piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 851056-25-2 CAPLUS
CN 2-Pyrrolidinone, 1-[(3-[[[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-
carbazol-6-yl)methyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 851056-26-3 CAPLUS
CN 4-Pyridinecarboxamide, N-[(1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-
carbazol-6-yl)-2-methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851056-27-4 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(cyclohexylamino)-2,3,4,9-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 851056-28-5 CAPLUS
CN Propanamide, N-[1-(cyclohexylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]- (9CI) (CA INDEX NAME)



RN 851056-29-6 CAPLUS
CN 1H-Carbazole-1,6-diamine, N1-cyclohexyl-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:232610 CAPLUS

DOCUMENT NUMBER: 142:316689

TITLE: Preparation of novel cycloalkyl[b] condensed indoles for treating human papillomaviruses
INVENTOR(S): Boggs, Sharon Davis; Catalano, John G.; Gudmundsson, Kristjan S.; D'Aurora Richardson, Leah; Sebahar, Paul Richard


PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 69 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023245	A1	20050317	WO 2004-US17982	20040607
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MG, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AE, BY, KG, KZ, MD, RU, T, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1658068	A1	20060524	EP 2004-754553	20040607
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007503434	T	20070222	JP 2006-524621	20040607
US 2006281804	A1	20061214	US 2006-569524	20060224
PRIORITY APPL. INFO.:			US 2003-497845P	P 20030826
			WO 2004-US17982	W 20040607

OTHER SOURCE(S): MARPAT 142:316689
GI



AB The present invention relates to cycloalkyl[b] condensed indoles (shown as
I: variables defined below: e.g.
6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-

L3 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
amine), including administration of pharmaceutically acceptable salts, solvents, and physiol. functional derivs. thereof, that are useful in the treatment of human papillomaviruses (HPVs), and also to the methods for the making and use of such compds. HPV inhibition values for 56 examples of I are reported. For I: n = 0-2; R is H or alkyl; X is NR2, O, or S(O)m; each R1 = H, halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, R10cycloalkyl, Ay, NHR10Ay, Het, NHR10Het, NHR10Het, OR2, OR2, OR2, R10OR2, NR2R3, NR2Ay, R10NR2R3, R10NR2Ay, R10C(O)R2, C(O)R2, CO2R2, R10CO2R2, C(O)NR2R3, C(O)Ay, C(O)NR2Ay, C(O)Het, C(O)NHR10Het, R10C(O)NR2R3, C(S)NR2R3, R10C(S)NR2R3, R10NHC(NH)NR2R3, C(NH)NR2R3, R10C(NH)NR2R3, S(O)2NR2R3, S(O)2NR2Ay, R10SO2NHCOR2, R10SO2NR2R3, R10SO2R2, S(O)mR2, cyano, nitro, or azido. Y is (un)substituted alkylene, (un)substituted cycloalkylene, (un)substituted alkenylene, (un)substituted cycloalkenylene, or (un)substituted alkynylene; d = 0-1; Z is R2, OR2, C(O)R2, C(O)R2, S(O)mR2, C(O)NR2R3, Het, or Ay, provided when d is 0, then Z is not Het or Ay; each m = 0-2; each R10 = alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene; p = 0-4; each of R2 and R3 H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, R10cycloalkyl, R10OH, R10(OR10)w, and R10NR5R6; w = 1-10; each of R5 and R6 = alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl; Ay = (un)substituted aryl; Het = (un)substituted 5- or 6-membered heterocyclyl or heteroaryl. Although the methods of prepn.

are not claimed, approx. 70 example prepn. are included. For example, 6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-amine was prepd. (52 %) from 6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-one, NH4OAc, and NaBH3CN in MeOH; the ketone was prepd. (88 %) by cyclization of cyclohexane-1,2-dione (4-chlorophenyl)hydrazone, which was prepd. (49 %) from the diazonium salt of 4-chloroaniline and 2-(hydroxymethylene)cyclohexanone.
IT 847988-07-2, 6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
RI: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
(chromatog. resolution; preparation of novel cycloalkyl[b] condensed indoles for treating human papillomaviruses)


RN 847988-07-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



IT 847988-06-1P, (1R)-6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 847988-08-3P,
(1R)-6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

L3 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1-amine hydrochloride
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of novel cycloalkyl[b] condensed indoles for treating human papillomaviruses)
 RN 847988-06-1 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 847988-08-3 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


IT 847987-99-9P, N-Cyclohexyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 847988-00-5P, N-(2,3-Dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 847988-24-3P

L3 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 847988-48-1 CAPLUS
 CN 1H-Carbazol-1-amine, 7-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


N-(2,3-Dihydro-1H-inden-2-yl)-6-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 847988-48-1P, 7-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of novel cycloalkyl[b] condensed indoles for treating human papillomaviruses)

RN 847987-99-9 CAPLUS
 CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 847988-00-5 CAPLUS
 CN 1H-Carbazol-1-amine, N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 847988-24-3 CAPLUS
 CN 1H-Carbazol-1-amine, N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1127334 CAPLUS
 DOCUMENT NUMBER: 142:74445
 TITLE: Preparation of tetrahydrocarbazole derivatives as human papillomaviruses inhibitors
 INVENTOR(S): Boggs, Sharon Davis; Gudmundsson, Kristjan S.; Richardson, Leah D'Aurora; Sebahar, Paul Richard
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 69 pp.
 DOCUMENT TYPE: CODEN: PIXKD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110999	A1	20041223	WO 2004-US17660	20040607
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GN, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004247676	A1	20041223	AU 2004-247676	20040607
CA 2528321	A1	20041223	CA 2004-2528321	20040607
EP 1654228	A1	20060510	EP 2004-776279	20040607
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004011085	A	20060725	BR 2004-11085	20040607
CN 1832921	A	20060913	CN 2004-80022227	20040607
JP 2007501284	T	20070125	JP 2006-533561	20040607
NO 2005005741	A	20060106	NO 2005-5741	20051205
US 2006161002	A1	20060720	US 2005-560013	20051208
PRIORITY APPLN. INFO.:			US 2003-477251P	P 20030610
			US 2003-497823P	P 20030826
			WO 2004-US17660	W 20040607

OTHER SOURCE(S): MARPAT 142:74445
 GI




AB Title compds. represented by the formula I [wherein R, R1 = independently

L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
halo(alkyl), (cyclo)alkenyl, (amino)aryl, etc.; X = NH, O or SOm; m = 0-2;
n = 0-2; p, q = independently 0-5; A = (hetero)aryl; and pharmaceutically acceptable salts, solvates, and physiol. functional derivs. thereof were prepd. as human papillomaviruses (HPV) inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of 4-chloroaniline with 2-(hydroxymethylene)cyclohexanone. II showed inhibition of HPV 16 with IC50 values of 10 nM in W-12 cellular assay. Thus, I and their pharmaceutical compns. are useful for the treatment or prophylaxis of conditions or disorders due to HPV infection, such as warts and cancers (no data).
IT 812649-13-1P, 6-Bromo-N-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation of tetrahydrocarbazole derivs. as human papilloma viruses inhibitors)
RN 812649-13-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)




IT 812649-14-2P, 6-Bromo-N-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 812649-15-3P, 6-Chloro-N-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-16-4P, 6-Chloro-N-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-17-5P, 6-Chloro-N-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-18-6P, 6-Chloro-N-(4-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-19-7P, 6-Chloro-N-(4-methylphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-20-0P, 6-Bromo-N-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-21-1P, 6-Bromo-N-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-22-2P, 6-Bromo-N-(4-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-23-3P, 6-Bromo-N-(pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 812649-24-4P, 6-Chloro-N-(pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-25-5P, 6-Chloro-N-(4,6-dimethoxypyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-26-6P, 6-Chloro-N-(4-methylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-27-7P, 6-Chloro-N-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-28-8P, 6-Bromo-N-(pyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 812649-15-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 812649-16-4 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 812649-17-5 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hydrochloride 812649-29-9P, 6-Bromo-N-(5-propylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-30-2P, 6-Methyl-N-(pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-31-3P, 6-Methoxy-N-(pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-32-4P, N-(4,6-Dimethoxypyrimidin-2-yl)-6-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 812649-33-5P, 6-Bromo-N-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 812649-34-6P, 6-Bromo-N-(5-(trifluoromethyl)pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-35-7P, 6-Bromo-N-(5-(trifluoromethyl)pyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-36-8P, 6-[(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]nicotinonitrile 812649-37-9P, N-(1,3-Benzothiazol-2-yl)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-38-0P, N-Pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-39-1P, 2-Bromo-N-(pyrimidin-2-yl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indol-6-amine 812649-41-5P, 6-Methyl-N-(pyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 812649-42-6P, Methyl 1-anilino-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylate 812649-43-7P, 6-[(6-Methyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]nicotinonitrile hydrochloride 812649-44-8P, N-Phenyl-6-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 812649-45-9P, N-Phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-46-0P, 6-Bromo-N-(3-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-47-1P, 6-Bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-48-2P, 6-Bromo-N-(1H-indol-5-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-49-3P, 6-Bromo-N-(2-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-50-6P, 6-Bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-51-7P, 6-Bromo-N-(2-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-52-8P, 6-Bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-53-9P, 6-Bromo-1-(4-fluorophenoxy)-2,3,4,9-tetrahydro-1H-carbazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrahydrocarbazole derivs. as human papilloma viruses inhibitors)
RN 812649-14-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)


L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-18-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-N-(4-fluorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-19-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 812649-20-0 CAPLUS

L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)- (9CI)
 (CA INDEX NAME)




RN 812649-21-1 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI)
 (CA INDEX NAME)




RN 812649-22-2 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
 (CA INDEX NAME)

L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 812649-25-5 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 812649-26-6 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 812649-27-7 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-28-8 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-2-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-23-3 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-2-pyrimidinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 812649-24-4 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-2-pyrimidinyl- (9CI)
 (CA INDEX NAME)




L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 812649-29-9 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(5-propyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 812649-30-2 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methyl-N-2-pyrimidinyl- (9CI)
 (CA INDEX NAME)




RN 812649-31-3 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methoxy-N-2-pyrimidinyl- (9CI)

L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-32-4 CAPLUS
CN 1H-Carbazol-1-amine,
N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro-6-
methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 812649-33-5 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-
tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 812649-34-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(5-(trifluoromethyl)-2-
pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 812649-35-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(5-(trifluoromethyl)-2-
pyrimidinyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-36-8 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-
yl)amino]- (9CI) (CA INDEX NAME)




RN 812649-37-9 CAPLUS
CN 1H-Carbazol-1-amine, N-2-benzothiazolyl-6-bromo-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 812649-38-0 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-2-pyrimidinyl- (9CI) (CA INDEX
NAME)


L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-39-1 CAPLUS
CN Cyclohept[b]indol-6-amine,
2-bromo-5,6,7,8,9,10-hexahydro-N-2-pyrimidinyl-
(9CI) (CA INDEX NAME)




RN 812649-41-5 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methyl-N-2-pyridinyl-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 812649-42-6 CAPLUS
CN 1H-Carbazole-6-carboxylic acid, 2,3,4,9-tetrahydro-1-(phenylamino)-,
methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-43-7 CAPLUS
CN 3-Pyridinecarbonitrile, 6-((2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)aminol-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 812649-44-8 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl-6-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 812649-45-9 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)


L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-49-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 812649-50-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-51-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-fluorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-46-0 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 812649-47-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-48-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-1H-indol-5-yl- (9CI) (CA INDEX NAME)


L3 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-52-8 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-53-9 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-1-(4-fluorophenoxy)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:726528 CAPLUS
 DOCUMENT NUMBER: 139:371731
 TITLE: Photophysical Properties of Directly Linked Linear Porphyrin Arrays
 AUTHOR(S): Kim, Dongho; Osuka, Atsuhiko
 CORPORATE SOURCE: National Creative Research Initiatives Center for Ultrafast Optical Characteristics Control and Department of Chemistry, Yonsei University, Seoul, 120-749, S. Korea
 SOURCE: Journal of Physical Chemistry A (2003), 107(42), 8791-8816
 CODEN: JPACPH; ISSN: 1089-5639
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A Variety of porphyrin arrays connected by diverse linkers have been envisaged and prepared for the applications in mol. photonics and electronics. From a viewpoint of operational requirements, the porphyrin arrays should have the very regular pigment arrangements which allow a facile light energy or charge flow along the arrays but do not result in the alteration of individual properties of the constituent pigments leading to formation of so-called energy or charge sink. In these respects, the directly coupled (orthogonal and fused) porphyrin arrays without any linkers are ideal, because the conformational heterogeneity mainly arising from a dihedral angle distribution between the neighboring porphyrin moieties should be minimized. In addition, the electronic effect of the linker can be disregarded in design strategy of mol. photonic devices, because the linker can also be considered as a transmission element in electronic communication. Considering these features, these types (orthogonal vs fused) of porphyrin arrays would be one of the most suitable synthetic mol. modules for the realization of mol. photonic and electronic devices. To unveil the functionalities of various porphyrin arrays, starting from the dihedral angle dependence on the photophys. properties of the porphyrin dimers, we have extended our knowledge to longer orthogonal and fused porphyrin arrays. Overall, the regularly arranged porphyrin arrays with ample electronic interactions will be promising in the applications such as mol. wires, sensors, optical nonlinear materials, and so on.
 IT 486445-26-5
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
 (photophys. properties of directly linked linear porphyrin arrays)
 RN 486445-26-5 CAPLUS
 CN Poly[(5,15-bis(4-(1,1-dimethyltridecyl)phenyl)-21H,23H-porphine-2,20,18:8,10,12-hexayl-κN21,κN22,κN23,κN24) zinc complex] (9CI) (CA INDEX NAME)


L3 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:726516 CAPLUS
 DOCUMENT NUMBER: 139:338148
 TITLE: An o-Iminothioquinone: Its Cycloaddition To Produce an Indologlycoside and Its Self-Dimerization To Form a Dithio-Diazocyclooctane, the Structure Assignment of Which Is Based on the DFT Prediction of Its IR Spectrum
 AUTHOR(S): Diep, Vinh; Dannenberg, J. J.; Franck, Richard W.
 CORPORATE SOURCE: Department of Chemistry, Hunter College, CUNY, New York, NY, 10021, USA
 SOURCE: Journal of Organic Chemistry (2003), 68(20), 7907-7910
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:338148
 AB An unusual heterodiene, an indolothiono quinone, undergoes cycloaddn. with a glycol to form an indole-N-glycoside. A novel dimer of the indolothionoquinone is assigned its structure on the basis of a match between its predicted and observed IR spectrum.
 IT 616883-32-0P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and structural characterization of an indologlycoside and its dimerization a dithio-diazocyclooctane)
 RN 616883-32-0 CAPLUS
 CN 1H-Indole-1,3(2H)-dione, 2-(9H-carbazol-1-ylthio)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


REFERENCE COUNT: 121 THERE ARE 121 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:870385 CAPLUS
 DOCUMENT NUMBER: 138:114936
 TITLE: Photophysical properties of porphyrin tapes
 AUTHOR(S): Cho, Hyun Sun; Jeong, Dae Hong; Cho, Sung; Kim, Dongho; Matsuzaki, Yoichi; Tanaka, Kazuyoshi; Tsuda, Akihiko; Osuka, Atsuhiko
 CORPORATE SOURCE: Center for Ultrafast Optical Characteristics Control and Department of Chemistry, Yonsei University, Seoul, 120-749, S. Korea
 SOURCE: Journal of the American Chemical Society (2002), 124(49), 14642-14654
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The novel fused Zn(II)porphyrin arrays (Tn, porphyrin tapes) in which the porphyrin macrocycles are triply linked at meso-meso, β-β, β-β positions have been investigated by steady-state and time-resolved spectroscopic measurements along with theor. MO calcs.
 The absorption spectra of the porphyrin tapes show a systematic downshift to the IR region as the number of porphyrin pigments increases in the arrays. The fused porphyrin arrays exhibit a rapid formation of the lowest excited states (for T2, .apprx.500 fs) via fast internal conversion processes upon photoexcitation at 400 nm (Soret bands), which is much faster than the internal conversion process of .apprx.1.2 ps observed for a monomeric Zn(II) porphyrin. The relaxation dynamics of the lowest excited states of the porphyrin tapes were accelerated from .apprx.4.5 ps for the T2 dimer to .apprx.0.3 ps for the T6 hexamer as the number of porphyrin units increases, being explained well by the energy gap law. The overall photophys. properties of the porphyrin tapes were observed to be in a sharp contrast to those of the orthogonal porphyrin arrays. The PPP-SCI calculated charge-transfer probability indicates that the lowest excited state of the porphyrin tapes (Tn) resembles a Wannier-type exciton closely, whereas the lowest excited state of the directly linked porphyrin arrays can be considered as a Frenkel-type exciton. Conclusively, these unique photophys. properties of the porphyrin tapes have aroused much interest in the fundamental photophysics of large flat organic mols. as well as in the possible applications as elec. wires, IR sensors, and nonlinear optical materials.
 IT 486445-26-5
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
 (photophys. properties of fused zinc porphyrin studied by steady-state and time-resolved spectroscopy and theor. MO calcs.)
 RN 486445-26-5 CAPLUS

L3 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Poly([5,15-bis[4-(1,1-dimethyltridecyl)phenyl]-21H,23H-porphine-2,20,18:8,10,12-hexayl- κ N21, κ N22, κ N23, κ N24] zinc complex) (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B


REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:436241 CAPLUS
 DOCUMENT NUMBER: 135:195514
 TITLE: Transformation of 5H,11H-indolo[3,2-b]carbazole through 5,11-didehydroindolo[3,2-b]carbazole
 Yudina, L. N.; Preobrazhenskaya, M. N.; Korolev, A.
 AUTHOR(S):
 M.
 CORPORATE SOURCE: G. F. Gauru Research Institute for the Search of New Antibiotics, Russian Academy of Medical Sciences, Moscow, 119867, Russia
 SOURCE: Chemistry of Heterocyclic Compounds (New York, NY, United States) (Translation of Khimiya Geterotsiklicheskikh Soedinenii) (2001), Volume Date 2000, 36(9), 1112-1113
 CODEN: CHCCAL; ISSN: 0009-3122
 PUBLISHER: Consultants Bureau
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:195514
 GI

L3 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT



AB Treatment of 5H,11H-indolo[3,2-b]carbazole (I) with DDQ gave 5,11-didehydroindolo[3,2-b]carbazole (II), which reacted with DDHQ to give III.
 IT 356039-99-1P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 356039-99-1 CAPLUS
 CN Benzenecarboximidic acid, 3,4-dichloro-6-cyano-5-[(5,11-dihydroindolo[3,2-b]carbazol-6-yl)oxy]-2-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:172500 CAPLUS
 DOCUMENT NUMBER: 130:305998
 TITLE: In vitro metabolism of a new anticancer agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β -D-glucopyranosyl)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans
 AUTHOR(S): Takenaga, N.; Hasegawa, T.; Ishii, M.; Ishizaki, H.; Hata, S.; Kamei, T.
 CORPORATE SOURCE: Drug Metabolism, Development Research Laboratories, Banyu Pharmaceutical Co., Ltd., Saitama, 360-0214, Japan
 SOURCE: Drug Metabolism and Disposition (1999), 27(2), 213-220
 PUBLISHER: CODEN: DMSAI; ISSN: 0090-9556
 DOCUMENT TYPE: American Society for Pharmacology and Experimental Therapeutics
 LANGUAGE: Journal
 AB The metabolism of 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β -D-glucopyranosyl)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506), a potent inhibitor of DNA topoisomerase I, was characterized in mice, rats, dogs, and humans in vitro. NB-506 was deformed to ED-501 in mouse and rat plasma with enzyme activity of 140 and 116 pmol/min/mg protein, resp. The enzyme activity in dog and human plasma was found to be less than 1.7 pmol/min/mg protein. In liver S9 and small intestine S9 samples from mice and rats, activity of the enzyme was very low. Also, there was no activity in the liver or small intestine of dogs and humans. The enzyme involved in the conversion of NB-506 to ED-501 in rat plasma is a rodent-specific serine enzyme with a mol. mass of 138KDa. The Vmax and Km values were 6.3 nmol/min/mL plasma and 54 μ M at an optimum pH of 7.4, resp. Although NB-506 was converted to ED-501 in dog and human plasma in vitro, no conversion was observed in mouse and rat plasma. In human plasma this conversion was not affected by heat treatment (100°C for 1 min), but was inhibited completely by 50 mM EDTA, indicating that the reaction is a chemical reaction catalyzed by metal ions. Although NB-506 was not metabolized by cytochrome P 450 isoenzymes in liver, this drug was glucuronized in mice, rats, and humans, but not in dogs. These results suggest that a species difference in the metabolism of NB-506 occurred in the liver as well as in plasma. There appeared to be species differences in the metabolism of NB-506 in vitro, correlating well with the species-dependent pharmacokinetics of this drug in vivo.
 IT 217187-87-6, ED 594
 RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
 (In vitro metabolism of a new anticancer agent, NB-506, in mice, rats, dogs, and humans)
 RN 217187-87-6 CAPLUS
 CN β -D-Glucopyranosiduronic acid, 6-(formylamino)-12- β -D-glucopyranosyl-6,7,12,13-tetrahydro-11-hydroxy-5,7-dioxo-5H-indolo[2,3-


L3 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 a]pyrrolo[3,4-c]carbazol-1-yl (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L3 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:172499 CAPLUS
 DOCUMENT NUMBER: 130:305997
 TITLE: In vivo metabolism of a new anticancer agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β -D-glucopyranosyl) 5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites
 AUTHOR(S): Takenaga, N.; Ishii, M.; Nakajima, S.; Hasegawa, T.; Iwasa, R.; Ishizaki, H.; Kamei, T.
 CORPORATE SOURCE: Drug Metabolism, Development Research Laboratories, Banyu Pharmaceutical Co., Ltd., Saitama, 360-0214, Japan
 SOURCE: Drug Metabolism and Disposition (1999), 27(2), 205-212
 PUBLISHER: CODEN: DMSAI; ISSN: 0090-9556
 DOCUMENT TYPE: American Society for Pharmacology and Experimental Therapeutics
 LANGUAGE: Journal
 AB 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β -D-glucopyranosyl)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506), a potent inhibitor of DNA topoisomerase I, is currently under development for the treatment of cancer. We investigated the pharmacokinetics of NB-506 after i.v. administration in rats and dogs. The plasma concentration of NB-506 decreased biexponentially in rats and dogs with terminal half-lives of approx. 2 h. The area under the curve increased nonlinearly with increasing dose in rats. In contrast, there was a linear relationship between the area under the curve and the dose in dogs. In rats, the plasma clearance decreased with increasing dose up to 187.5 mg/m² but remained virtually unchanged at the highest dose. The Vdss of NB-506 in rats and dogs was much greater than the plasma volume, indicating that NB-506 is highly distributed to tissue from plasma in these animals. There were marked species differences in the plasma concns. of ED-501 after i.v. administration of NB-506 to rats and dogs. To better understand the mechanisms of nonlinear pharmacokinetics in rats, in vivo metabolites were determined After i.v. administration of [14C]NB-506 to rats, two unknown metabolites (RBM-1 and RBM-2), deformed metabolite (ED-501), and unchanged drug (NB-506) were identified. Mass and NMR spectra anal. revealed that RBM-1 is an 11-O-glucuronide of NB-506 (ED-594) and that RBM-2 is an 11-O-glucuronide of ED-501 (ED-595). In this study, the pharmacokinetics of NB-506 was demonstrated to be nonlinear in rats, probably because of saturation of the enzyme systems catalyzing the deformylation and glucuronidation of NB-506 in rats.
 IT 217187-87-6, ED 594 217188-11-9, ED 595
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence)
 (In vivo metabolism of a new anticancer agent NB-506 in rats and dogs)
 RN 217187-87-6 CAPLUS
 CN β -D-Glucopyranosiduronic acid, 6-(formylamino)-12- β -D-glucopyranosyl-6,7,12,13-tetrahydro-11-hydroxy-5,7-dioxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-1-yl (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.



RN 217188-11-9 CAPLUS
 CN β -D-Glucopyranosiduronic acid, 6-amino-12- β -D-glucopyranosyl-6,7,12,13-tetrahydro-11-hydroxy-5,7-dioxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-1-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L3 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:667211 CAPLUS

DOCUMENT NUMBER: 130:32652

TITLE: Metabolism of carvedilol in dogs, rats, and mice

AUTHOR(S): Schaefer, William H.; Politowski, James; Kwang, Bruce;

Dixon, Frank, Jr.; Goalwin, Anne; Gutzait, Louis; Anderson, Kathleen; Debrosse, Charles; Bean, Mark; Rhodes, Gerald R.

CORPORATE SOURCE: Departments of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, USA

SOURCE: Drug Metabolism and Disposition (1998), 26(10), 958-969

CODEN: DMDSAI; ISSN: 0090-9556

PUBLISHER: Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The excretion and biotransformation of carvedilol

[1-(carbazolyl-(4)-oxy)-

3-[(2-methoxyphenoxyethyl)amino]-2-propanol], a new, multiple-action, neurohormonal antagonist that exhibits the combined pharmacol. activities of β -adrenoreceptor antagonism, vasodilation, and antioxidn., were investigated in dogs, rats, and mice. Carvedilol was absorbed well, and biliary secretion was predominant in each species. Carvedilol was metabolized extensively in each species, and elimination of unchanged compound was minor in bile duct-catheterized rats and dogs. In dogs, glucuronidation of the parent compound and hydroxylation of the carbazolyl

ring, with subsequent glucuronidation, were the major metabolic pathways. Rats showed the simplest metabolite profile: the primary metabolites were formed by hydroxylation of the carbazolyl ring, with subsequent glucuronidation. Mice displayed the most complicated metabolite profile: glucuronidation of the parent compound and hydroxylation of either the carbazolyl or Ph ring, with subsequent glucuronidation, were the major metabolic routes. O-Dealkylation was a minor pathway in all species examined.

IT 131087-98-4 131087-99-5

RL: BPR (Biological process); BSU (Biological study, unclassified); MPM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)

(metabolism of carvedilol in dogs, rats, and mice)


RN 131087-98-4 CAPLUS

CN β -D-Glucopyranosiduronic acid, 5-[2-hydroxy-3-[[2-(2-methoxyphenoxy)ethyl]amino]propoxy]-9H-carbazol-1-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


L3 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 131087-99-5 CAPLUS

CN β -D-Glucopyranosiduronic acid, 5-[2-hydroxy-3-[[2-(2-methoxyphenoxy)ethyl]amino]propoxy]-9H-carbazol-1-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:612719 CAPLUS

DOCUMENT NUMBER: 130:47074

TITLE: Studies on the disposition of [14C]NB-506: plasma concentration-time profile, distribution, metabolism and excretion of [14C]NB-506 after single and

repeated

AUTHOR(S): Ishii, Mikio; Takenaga, Norihiro; Ishizaki, Hiroyuki; Kamei, Toshio; Minomiy, Shin-ichi; Esumi, Yoshio

CORPORATE SOURCE: Development Research Laboratories, Banyu Pharmaceutical Co., Ltd., Saitama, 360-0214, Japan

SOURCE: Yakubutsu Dotai (1998), 13(4), 337-345

CODEN: YADOEL; ISSN: 0916-1139

PUBLISHER: Nippon Yakubutsu Dotai Gakkai

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB Plasma concentration-time profile, distribution, metabolism and excretion of

[14C]NB-506 were investigated in male and female rats after single and repeated i.v. administration. 1. After a single i.v. administration of [14C]NB-506 to male rats, plasma levels of radioactivity decreased triexponentially with the $t_{1/2}$ of 22 min, 2.4 h and 2.1 day. The pharmacokinetic parameters obtained from female rats, were similar to those in male rats. 2. After a single i.v. administration of [14C]NB-506 to male rats, the maximum concentration in almost all tissues was

observed at 10 min.

The radioactivity was highly distributed in liver followed by kidney, lung, mandibular gland, skin and pancreas. At 24 h post dose, the radioactivities in tissues were almost same as that of plasma except

liver

and kidney, and then decreased and were lower than 10% of maximum radioactivity at 72 h. 3. Within 120 h after a single i.v.

administration

of [14C]NB-506 to male rats, 9.8 and 89.3% of dose were excreted into urine and feces, resp. Biliary excretion was 82.9% in male rats. The enterohepatic circulation of [14C]NB-506 was not observed in male rats.

The

excretion of radioactivity in female rats was similar to that in male rats. 4. After a single i.v. administration of [14C]NB-506 to male rats, 40.0, 23.8, 6.3 and 1.5% of dose were excreted to bile (0-6 h) as intact NB-506, NB-506 glucuronide (ED-594), NB-506 deformed form (ED-501) and ED-501 glucuronide (ED-595), resp. The 6.2% of administered dose in

urine

(0-4 h) corresponded to intact NB-506 and 0.7% of dose was excreted to urine as ED-594 and ED-501. 5. The plasma levels of radioactivity at 5 min, 4, 24 h after the 5th dosing were higher than those after the first dosing. Moreover, the levels of AUC(0- ∞) and $t_{1/2\gamma}$ of the 5th dosing were 2.1 and 2.3 times higher than those of the first dosing,

resp.


These results indicate that [14C]NB-506 tend to accumulate in plasma

after

the multiple dosing. The accumulation ratio was calculated based on the plasma levels of radioactivity at 24 h after the first and the 5th dosing;

this value was 3.85. On the other hand, the accumulation factor, which

L3 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

was estd. from the elimination rate const., was calcd. to be 3.56. Therefore, the accumulation ratio was almost of the same value as the predicted accumulation factor. These results suggest that it is possible to predict the disposition of [14C]NB-506 after the multiple dosing and the possibility that the crucial accumulation of [14C]NB-506 may arise from the multiple dosing is low. 6. No change in the daily excretion of radioactivity in urine and feces was obsd. during 5-day repeated administration. Within 168 h after the last dosing, urinary and fecal excretion of radioactivity were 7.5 and 90.1% of dose, resp., indicating that the main elimination route is fecal excretion.

IT

217187-87-6, ED 594 217188-11-9, ED 595

RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)


(studies on the disposition of [14C]NB-506: plasma concentration-time

profile, distribution, metabolism and excretion of [14C]NB-506 after single and repeated i.v. administration in rats)

RN 217187-87-6 CAPLUS

CN β -D-Glucopyranosiduronic acid, 6-(formylamino)-12- β -D-glucopyranosyl-6,7,12,13-tetrahydro-11-hydroxy-5,7-dioxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-1-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217188-11-9 CAPLUS

CN β -D-Glucopyranosiduronic acid, 6-amino-12- β -D-glucopyranosyl-6,7,12,13-tetrahydro-11-hydroxy-5,7-dioxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-1-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:686731 CAPLUS

DOCUMENT NUMBER: 123:113989

TITLE: Stabilization of polyethylene against thermal oxidation

INVENTOR(S): Daszkiewicz, Zdzislaw; Sudol, Marek; Kyzioł, Janusz B.; Nowakowska, Maria

PATENT ASSIGNEE(S): Wyzsza Szkola Pedagogiczna im. Powstancow Slaskich, Pol.

SOURCE: Pol., 6 pp.

CODEN: POXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Polish

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PL 159744	B1	19930129	PL 1989-282691	19891207

PRIORITY APPLN. INFO.: PL 1989-282691 19891207

OTHER SOURCE(S): MARPAT 123:113989

GI



AB Carbazole derivs. I [R = H, Et, or PhCH₂, R₁ = 1- or 3-(2-naphthylamino)] are useful for the title process at 0.05-0.5% concentration


IT 159594-75-9, 1-(2-Naphthylamino)carbazole

RL: MOA (Modifier or additive use); USES (Uses)

(naphthylaminocarbazole derivs. as antioxidants for polyethylene)

RN 159594-75-9 CAPLUS


CN 9H-Carbazol-1-amine, N-2-naphthalenyl- (9CI) (CA INDEX NAME)




L3 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:240048 CAPLUS
 DOCUMENT NUMBER: 122:31324
 TITLE: Method for preparation of new naphthyl derivatives of aminocarbazoles useful as polymer stabilizers
 INVENTOR(S): Daszkiewicz, Zdzislaw; Sudol, Marek; Kyzioł, Janusz
 PATENT ASSIGNEE(S): Wyższa Szkoła Pedagogiczna im. Powstańców Śląskich, Pol.
 SOURCE: Pol., 4 pp.
 CODEN: POXXA7
 DOCUMENT TYPE: Patent
 LANGUAGE: Polish
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PL 159916	B1	19930129	PL 1989-278902	19890414
PRIORITY APPLN. INFO.:			PL 1989-278902	19890414

OTHER SOURCE(S): MARPAT 122:31324
 GI




I



II

AB Title compds. I [R = H, alkyl, CH₂Ph] and II, useful as antioxidants and heat stabilizers for olefinic polymers (no data), are prepared by fusion of corresponding 3-amino-9-R-substituted carbazoles or 1-aminocarbazole with a 5- to 15-fold molar excess of 2-naphthol. For example, 0.1 mol 3-amino-9-ethylcarbazole was dissolved in 1 mol molten 2-naphthol, and the mixture was kept at 410 K for 24 h with subsurface bubbling of N₂. After addition of 0.1 L DMF to decrease viscosity, the mixture was poured into a solution of 80 g NaOH in 0.8 L H₂O, and the precipitate was filtered, washed, and dissolved in 1:1 THF-toluene. After washing with base and acid to remove

L3 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 starting materials, the soln. was concd. to give cryst. I (R = Et) in 67% yield. Similar reaction of crude 3-aminocarbazole contg. some 1-amino isomer (prepn. of mixt. given) with a 10-fold excess of 2-naphthol gave 82% I (R = H) plus some II.
 IT 159594-75-9P, 1-(2-Naphthylamino)carbazole
 RL: MOA (Modifier or additive use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (Preparation of naphthylaminocarbazoles as antioxidants and heat stabilizers for polymers)
 RN 159594-75-9 CAPLUS
 CN 9H-Carbazol-1-amine, N-2-naphthalenyl- (9CI) (CA INDEX NAME)



L3 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1992:469729 CAPLUS
 DOCUMENT NUMBER: 117:69729
 TITLE: Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,4a,8a-hexahydrocyclopent[b]indoles and related compounds
 INVENTOR(S): Ong, Helen H.; O'Malley, Gerard J.; Merriman, Michael C.; Palemmo, Mark G.
 PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Inc., USA
 SOURCE: U.S., 22 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5100891	A	19920331	US 1991-642952	19910118
US 5192789	A	19930309	US 1992-818703	19920109
RO 112505	B1	19971030	RO 1992-149168	19920115
FI 9200192	A	19920719	FI 1992-192	19920116
FI 102174	B	19961030		
FI 102174	B1	19961030		
PL 167465	B1	19950930	PL 1992-296651	19920116
PL 169417	B1	19960731	PL 1992-293209	19920116
CZ 282732	B6	19970917	CZ 1992-129	19920116
CA 2059610	A1	19920719	CA 1992-2059610	19920117
CA 2059610	C	20020402		
NO 9200235	A	19920720	NO 1992-235	19920117
NO 178397	B	19951211		
NO 178397	C	19960320		
AU 9210279	A	19920723	AU 1992-10279	19920117
AU 650315	B2	19940616		
ZA 9200341	A	19920930	ZA 1992-341	19920117
JP 04334367	A	19921120	JP 1992-6681	19920117
HU 67027	A2	19950130	HU 1992-172	19920117
RU 2077530	C1	19970420	RU 1992-5010763	19920117
EP 496314	A1	19920729	EP 1992-100816	19920118
EP 496314	B1	19971001		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
AT 158790	T	19971015	AT 1992-100816	19920118
ES 2109953	T3	19980201	ES 1992-100816	19920118
BR 9200171	A	19921006	BR 1992-171	19920121
US 5298626	A	19940329	US 1992-976067	19921113
US 5472975	A	19951205	US 1994-177035	19940104
US 5514700	A	19960507	US 1995-472586	19950607
FI 9700396	A	19970130	FI 1997-396	19970130
FI 107150	B1	20010615		
FI 9700397	A	19970130	FI 1997-397	19970130
FI 106713	B1	20010330		
FI 2000001775	A	20000810	FI 2000-1775	20000810
FI 107919	B1	20011031		

PRIORITY APPLN. INFO.:

US 1991-642952	A2	19910118
US 1992-818703	A3	19920109
FI 1992-192	A	19920116

L3 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 US 1992-976067 A3 19921113
 US 1994-177035 A3 19940104


OTHER SOURCE(S): CASREACT 117:69729; MARPAT 117:69729
 GI



AB Title compds. I [n = 2, 3, 4, 5; X = H, lower alkyl, lower alkoxy, OH, halo, CF₃, NO₂; R₁ = H, lower alkyl, lower alkenyl, lower alkynyl, amino lower alkyl, cycloalkyl, cycloalkenyl, aryl, pyrrolidinoalkyl, piperidinoalkyl, morpholinoalkyl, etc.; R₂ = H, lower alkyl, formyl, lower alkylcarbonyl, benzyloxycarbonyl, etc.; NR₁R₂ = pyrrolidino, piperidino, morpholino, piperazino, etc.; R₃ = H, lower alkyl, aryl lower alkyl, lower alkylcarbonyl, lower alkoxyalkyl, etc.; R₄ = O₂CNR₅R₆ (R₅ = lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, etc.; R₆ = H, lower alkyl, aryl, aryl lower alkyl; NR₅R₆ = pyrrolidino, piperidino, morpholino, piperazino, etc.) were prepared as agents for alleviating various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease. Thus, 1,2-dihydrocyclopent[b]indol-3(2H)-one II (R₇ = H) was acylated with ClCH₂COCl in the presence of AlCl₃ in CH₂Cl₂ to give II (R₇ = ClCH₂CO), which was oxidized with m-chloroperoxybenzoic acid in the presence of Na phosphate in CHCl₃ to give IV (R₇ = ClCH₂CO). The latter was treated with cyclopropylamine in the presence of TiCl₄ in toluene to give the imine III, which was reduced with NaBH₄ in Me₂CHOH/MeOH (5:1) to give the amine IV (R₈ = H), which was treated with Me isocyanate in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene in CH₂Cl₂ to give IV (R₈ = MeNHC=O) (V). V at 3.5 μM inhibited brain acetylcholinesterase by 50%; V also inhibited monoamine oxidases.

IT 142283-79-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RN 142283-79-2 CAPLUS
 CN Cyclopent[b]indol-3-amine, N-cyclopropyl-1,2,3,4-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

L3 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:679992 CAPLUS
 DOCUMENT NUMBER: 115:279992
 TITLE: Preparation and formulation of carbazole-3,4-dicarboximides and analogs as antitumor agents
 INVENTOR(S): Nagai, Takashi; Myokan, Isao; Keishi, Funaki; Ohta, Kenji; Taya, Nobuhisa; Miyabara, Shinji; Shibata, Masaaki; Mikami, Hidetada; Hori, Takako
 PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan
 SOURCE: Ger. Offen., 98 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4034687	A1	19910502	DE 1990-4034687	19901031
DE 4034687	C2	19991202		
JP 04178387	A	19920625	JP 1990-288069	19901025
JP 3027599	B2	20000404		
US 5166204	A	19921124	US 1990-605430	19901030
CA 2028960	A1	19910502	CA 1990-2028960	19901031
CA 2028960	C	19990119		
DK 9002618	A	19910502	DK 1990-2618	19901031
NL 9002366	A	19910603	NL 1990-2366	19901031
FR 2655345	A1	19910607	FR 1990-13552	19901031
GB 2239013	A	19910619	GB 1990-23568	19901031
GB 2239013	B	19930602		
SE 9003476	A	19920501	SE 1990-3476	19901031
SE 509700	C2	19990222		
BE 1004069	A3	19920915	BE 1990-1032	19901031
CH 682151	A5	19930730	CH 1990-3464	19901031
PRIORITY APPLN. INFO.:				
			JP 1989-285548	A 19891101
			JP 1990-205443	A 19900802
			JP 1990-288069	A 19901025

OTHER SOURCE(S): MARPAT 115:279992
 GI




L3 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The title compds. [I; G = O, SO_n, NR₂; R₁, R₃ = H, halo, NO₂, OH, (un)substituted alkyl, aryl, etc.; R₂ = (un)substituted (ar)alkyl, aryl, CONH₂, acyl; R₆R₇ = CON(Y₂)CO; Y = bond, alkylene; Z = halo, (un)protected OH, NR₄R₅, etc.; R₄,R₅ = H, (un)substituted (cyclo)alkyl, aralkyl, acyl, aryl; NR₄R₅ = (un)substituted heterocyclyl; n = 0-2] were prepared. Thus, N-benzyl-4-oxocyclohexane-1,2-dicarboximide was cyclocondensed with PhNNH₂ and 1 of the isomeric products aromatized with DDQ to give title compound II (R = CH₂Ph, R₁ = R₃ = H) which was converted in 2 steps to
 II (R = CH₂CH₂NMe₂) (III; R₁ = R₃ = H). III (R₁ = OH, R₃ = Me) gave life extension of >377% that of controls in mice with i.p. L-1210-ascites tumor cells at 1 mg/kg i.p.
 IT 135555-15-6P 135555-21-4P 135555-52-1P
 135555-53-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of antitumor agents)
 RN 135555-15-6 CAPLUS
 CN 9H-Carbazole-3,4-dicarboxylic acid, 6-methoxy-1-phenoxy-, dimethyl ester (9CI) (CA INDEX NAME)




RN 135555-21-4 CAPLUS
 CN 1H-Furo[3,4-c]carbazole-1,3(6H)-dione, 9-methoxy-5-phenoxy- (9CI) (CA INDEX NAME)




RN 135555-52-1 CAPLUS
 CN 9H-Carbazole-3,4-dicarboxylic acid, 1-(4-methoxyphenoxy)-6-(phenylmethoxy)-, dimethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 135555-53-2 CAPLUS
 CN 1H-Furo[3,4-c]carbazole-1,3(6H)-dione, 5-(4-methoxyphenoxy)-9-(phenylmethoxy)- (9CI) (CA INDEX NAME)




IT 135551-87-0P 135551-88-1P 135552-28-2P
 135552-29-3P 135553-08-1P 135553-09-2P
 135553-16-1P 135553-17-2P 135553-18-3P
 135553-19-4P 135553-24-1P 135553-25-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as antitumor agent)
 RN 135551-87-0 CAPLUS
 CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(dimethylamino)ethyl]-9-methoxy-5-phenoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 135551-88-1 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(dimethylamino)ethyl]-9-methoxy-5-phenoxy-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 135552-28-2 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(dimethylamino)ethyl]-9-hydroxy-5-phenoxy- (9CI) (CA INDEX NAME)




RN 135552-29-3 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(dimethylamino)ethyl]-9-hydroxy-5-phenoxy-, hydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 135553-16-1 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(dimethylamino)ethyl]-9-hydroxy-5-(4-hydroxyphenoxy)- (9CI) (CA INDEX NAME)




RN 135553-17-2 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(dimethylamino)ethyl]-9-hydroxy-5-(4-hydroxyphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 135553-18-3 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(diethylamino)ethyl]-9-hydroxy-5-phenoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● x HCl

RN 135553-08-1 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(diethylamino)ethyl]-9-methoxy-5-phenoxy- (9CI) (CA INDEX NAME)




RN 135553-09-2 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(dimethylamino)ethyl]-5-(4-methoxyphenoxy)-9-(phenylmethoxy)- (9CI) (CA INDEX NAME)




L3 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 135553-19-4 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(diethylamino)ethyl]-9-hydroxy-5-phenoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 135553-24-1 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(dimethylamino)ethyl]-9-hydroxy-5-(4-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 135553-25-2 CAPLUS
CN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, 2-[2-(dimethylamino)ethyl]-9-hydroxy-5-(4-methoxyphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

L3 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 1991:574019 CAPLUS
 DOCUMENT NUMBER: 115:174019
 TITLE: Stereoselective metabolism of carvedilol in the rat: use of enantiomerically radiolabeled pseudoracemates
 AUTHOR(S): Fujimaki, Masayoshi; Shintani, Shozou; Hakuai, Hideo
 CORPORATE SOURCE: Res. Inst., Daiichi Pharm. Co., Ltd., Tokyo, 134, Japan
 SOURCE: Drug Metabolism and Disposition (1991), 19(4), 749-53
 CODEN: DMDSAI; ISSN: 0090-9556
 JOURNAL
 DOCUMENT TYPE: English
 LANGUAGE: English
 AB 14C-labeled R(+) and S(-)-carvedilol enantiomers were prepared by direct resolution of 14C-labeled racemic carvedilol on a chiral HPLC column.
 Two enantiomerically radiolabeled carvedilol pseudoracemates, 14C-labeled R(+)/unlabeled S(-)-carvedilol and 14C-labeled S(-)/unlabeled R(+)-carvedilol, were reconstituted and administered orally and i.v. to sep. groups of bile duct-cannulated rats to determine the biliary excretion of carvedilol enantiomers and the stereochem. composition of metabolites excreted into the bile. Oral administration of these pseudoracemates produced no enantiomeric difference in the biliary excretion of the radioactivity derived from the enantiomers, whereas i.v. administration did result in an enantiomeric difference: the biliary excretion rate of the radioactivity derived from R(+)-enantiomer was higher than that from S(-)-enantiomer. After administration by the two routes, two carbazole ring-hydroxylated glucuronides, 1-hydroxycarvedilol O-glucuronide (1-OHCG) and 8-hydroxycarvedilol O-glucuronide (8-OHCG), were detected as the major metabolites in the bile. The S/R enantiomer ratios of 1-OHCG were 0.59 for oral dosing and 0.43 for i.v. dosing, suggesting that the formation of 1-OHCG is selective for R(+)-enantiomer, while the S/R ratios of 8-OHCG showed values of 3.29 and 2.63 for oral and i.v. administrations, resp., favoring S(-)-enantiomer. Since corresponding hydroxylated metabolites are rapidly biotransformed to glucuronides that are excreted predominantly in the bile, the stereoselectivity of these glucuronides presumably reflects that of carvedilol ring hydroxylation.
 IT 136657-37-9 136657-38-0 136657-39-1 136657-40-4
 RL: FORM (Formation, nonpreparative)
 (formation of, as carvedilol metabolite, after oral and i.v. administration of racemate, stereoselectivity in)
 RN 136657-37-9 CAPLUS
 CN β -D-Glucopyranosiduronic acid, 4-[2-hydroxy-3-[(2-(2-methoxyphenoxy)ethyl)amino]propoxy]-9H-carbazol-1-yl, (R)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L3 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 136657-38-0 CAPLUS
 CN β -D-Glucopyranosiduronic acid, 4-[2-hydroxy-3-[(2-(2-methoxyphenoxy)ethyl)amino]propoxy]-9H-carbazol-1-yl, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 136657-39-1 CAPLUS
 CN β -D-Glucopyranosiduronic acid, 5-[2-hydroxy-3-[(2-(2-methoxyphenoxy)ethyl)amino]propoxy]-9H-carbazol-1-yl, (R)- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 136657-40-4 CAPLUS
 CN β -D-Glucopyranosiduronic acid, 5-[2-hydroxy-3-[(2-(2-methoxyphenoxy)ethyl)amino]propoxy]-9H-carbazol-1-yl, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1991:17038 CAPLUS
 DOCUMENT NUMBER: 114:17038
 TITLE: Identification of two major biliary metabolites of carvedilol in rats
 AUTHOR(S): Fujimaki, M.; Hakusui, H.
 CORPORATE SOURCE: Res. Inst., Daiichi Pharm. Co., Ltd., Tokyo, 134, Japan
 SOURCE: Xenobiotica (1990), 20(10), 1025-34
 CODEN: XENOBH; ISSN: 0049-8254
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB After sep. administration of R(+)-, S(-)-, and 14-C-labeled (±)-carvedilol [(±)-I] to rats at an oral dose of 10 mg/kg, the metabolic pattern in the bile was studied using (HPLC) with radioactivity and UV monitoring. Two major metabolites, present in the bile, accounted for 39 and 22%, resp., of the dose. These metabolites were characterized as 1-hydroxycarvedilol O-glucuronide (II) and 8-hydroxycarvedilol O-glucuronide (III), resp., from fast atom bombardment-mass spectrometry, 1H-NMR and enzymic hydrolysis. Oral administration of R(+)-carvedilol


led to highly selective excretion of II in bile, whereas S(-)-carvedilol resulted predominantly in excretion of III rather than II.

IT 131087-98-4 131087-99-5
 RL: BIOL (Biological study)
 (as carvedilol metabolite, in bile)

RN 131087-98-4 CAPLUS
 CN β-D-Glucopyranosiduronic acid, 4-[2-hydroxy-3-[[2-(2-methoxyphenoxy)ethyl]amino]propoxy]-9H-carbazol-1-yl (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 131087-99-5 CAPLUS
 CN β-D-Glucopyranosiduronic acid, 5-[2-hydroxy-3-[[2-(2-methoxyphenoxy)ethyl]amino]propoxy]-9H-carbazol-1-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L3 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:157993 CAPLUS
 DOCUMENT NUMBER: 112:157993
 TITLE: Photo-Fries rearrangements in N-sulfonylcarbazoles
 AUTHOR(S): Chakrabarti, Amit; Biswas, Goutam K.; Chakraborty, D. P.
 CORPORATE SOURCE: Dep. Chem., Bose Inst., Calcutta, 700009, India
 SOURCE: Tetrahedron (1989), 45(16), 5059-64
 CODEN: TETRAH; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 112:157993
 GI




AB Photo-Fries rearrangement of N-sulfonyl carbazoles I (R = Ph, C6H4Me-4, Me) afforded the resp. 1- and 3-sulfonyl carbazoles in 29-55% yield. N-Benzoylcarbazole did not undergo similar rearrangement.

IT 126230-30-6P 126230-31-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 126230-30-6 CAPLUS
 CN 9H-Carbazole, 1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 126230-31-7 CAPLUS
 CN 9H-Carbazole, 1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L3 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:449967 CAPLUS
 DOCUMENT NUMBER: 111:49967
 TITLE: Antiviral activity of 1-amino-1,2,3,4-tetrahydrocarbazoles
 AUTHOR(S): Akalaeva, T. V.; Bokanov, A. I.; Ivanov, P. Yu.; Nikolaeva, I. S.; Pushkina, T. V.; Fomina, A. N.; Shvedov, V. I.
 CORPORATE SOURCE: VNIKhFI, Moscow, USSR
 SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1989), 23(3), 299-302
 DOCUMENT TYPE: CODEN: KHFFZAN; ISSN: 0023-1134
 LANGUAGE: Journal
 GI: Russian




AB I [X = H, Me, F, Cl; R = e.g., CH₂CH(OMe)₂, (CH₂)₃NMe₂, or CH₂CH₂OPh] were prepared by the cyclization of monophenyl hydrazones of cyclohexane-1,2-dione followed by treatment with corresponding amines and NaBH₄ reduction. The antiviral activity of these compds. was studied against DNA-viruses (herpes simplex) and RNA viruses both in culture cells and in mice. I (R = PhCH₂CH₂ and X = Me) showed activity against both herpes and influenza viruses in vivo. The activity was dependent on the structure of the compds. e.g., I (R = CHMePh, X = Me; and R = CH₂CH₂Ph and X = H) were inactive.
 IT 118498-97-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and antiviral activity of)
 RN 118498-97-8 CAPLUS
 CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L3 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:54362 CAPLUS
 DOCUMENT NUMBER: 110:54362
 TITLE: Synthesis and in vitro antituberculous activity of alkylaminotetrahydrocarbazoles
 AUTHOR(S): Filitis, L. N.; Akalaeva, T. V.; Amel'kin, O. Yu.; Bokanov, A. I.; Ivanov, P. Yu.; Shvedov, V. I.
 CORPORATE SOURCE: VNIKhFI, Moscow, USSR
 SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1988), 22(10), 1217-22
 DOCUMENT TYPE: CODEN: KHFFZAN; ISSN: 0023-1134
 LANGUAGE: Journal
 OTHER SOURCE(S): CASREACT 110:54362
 AB 1-Aminotetrahydrocarbazoles with various substituents at the exocyclic nitrogen atom were synthesized and tested for their activity against Koch's bacilli, opportunistic mycobacteria, and saprophytes. All compds. were able to suppress the growth of mycobacteria in vitro but no therapeutic effect was found in mice with exptl. tuberculosis.
 IT 118498-97-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and tuberculostatic activity of, structure in relation to)
 RN 118498-97-8 CAPLUS
 CN 1H-Carbazol-1-amine, N-cyclohexyl-2,3,4,9-tetrahydro-6-methyl- (9CI) (CA INDEX NAME)





L3 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1988:493909 CAPLUS
 DOCUMENT NUMBER: 109:93909
 TITLE: The effect of heteroatomic substitutions on the band gap of polyacetylene and poly(p-phenylene)
 derivatives
 AUTHOR(S): Lee, Yong Sok; Kertesz, Miklos
 CORPORATE SOURCE: Dep. Chem., Georgetown Univ., Washington, DC, 20057, USA
 SOURCE: Journal of Chemical Physics (1988), 88(4), 2609-17
 CODEN: JCPSA6; ISSN: 0021-9606
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The electronic structures of poly(p-phenylene) (I), polyacetylene (II), and their derivs. with small energy gaps were studied by the Hückel and MNDO crystal orbital methods. The effect of nuclear relaxation and heteroat. substitution on the energy gaps (Eg) were taken into account by complete geometry optimization using periodic boundary conditions as opposed to earlier cluster-based calcs. Calcs. were done on: polypyrrole (III), polythiophene (IV), poly(isothianaphthene) (V), poly(5,5'-bithiophenemethenyl) (VI), and poly(5,5'-bipyrrolemethenyl) (VII). Energetics and band gaps for the 2 isomeric forms, the quinoid and aromatic structures of III and IV are discussed and critical compared with previous calcs. PMO theory is invoked to explain the narrower Eg for V, VI, and VII relative to that of II. Calcs. for I derivs., (polybenzo[b]thiophene, polybenzo[b,f]thieno[3,4-c]thiophene, and polybenzo[b,f]pyrrolo[3,4-c]pyrrole) show that the Eg of some of these polymers is substantially smaller than that of I. Comments on ways to stabilize structures with desired small energy gaps are made. A correlation of the Eg with heteroatom perturbation and geometrical relaxation is given. The Eg is controlled not by aromatic vs. quinoid contributions, but by the geometrical and heteroat. effects on the frontier orbitals of the polymer.
 IT 115980-71-7
 RL: PRP (Properties)
 (band gap of)
 RN 115980-71-7 CAPLUS
 CN Poly(4,8-dihydropyrrolo[2,3,4,5-def]carbazole-1,2,3:5,6,7-hexayl) (9CI)
 (CA INDEX NAME)

L3 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L3 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1982:438899 CAPLUS
 DOCUMENT NUMBER: 97:38899
 TITLE: Competitive cyclization of singlet and triplet nitrenes. Part 10. The choice between carbazole and phenothiazine formation
 AUTHOR(S): Hawkins, David G.; Meth-Cohn, Otto
 CORPORATE SOURCE: Dep. Chem. Appl. Chem., Univ. Salford, Salford, M5 4WT, UK
 SOURCE: Journal of Chemical Research, Synopses (1982), (4), 105
 CODEN: JRPSDC; ISSN: 0308-2342
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 97:38899
 GI

L3 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Thermal decomposition of the biphenyl I (R = N3) (II), prepared from 2,6-Cl2C6H3NO2 by sequential amination, phenylation, thiotolylolation, and azidation, in 1,2,4-Cl3C6H3 for 3 h gave 81% carbazole II, whereas on hot PhOMe-sensitized photolysis 61% phenothiazine III was obtained. Deoxygenation of I (R = NO2) in 1,2,4-Cl3C6H3 under reflux for 24 h gave 37% II. The results are discussed in terms of a singlet nitrene origin for carbazole formation, with either singlet or triplet spin state giving the phenothiazine.
 IT 82342-01-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and desulfurization of)
 RN 82342-01-6 CAPLUS
 CN 9H-Carbazole, 1-[(4-methylphenyl)thio]- (9CI) (CA INDEX NAME)


L3 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1981:76484 CAPLUS
 DOCUMENT NUMBER: 94:76484
 TITLE: Metabolism of carprofen, a nonsteroidal
 antiinflammatory agent, in rats, dogs, and humans
 AUTHOR(S): Rubio, F.; Seawall, S.; Pocelinko, R.; DeBarbieri,
 B.;
 Benz, W.; Berger, L.; Morgan, L.; Pao, J.; Williams,
 T. H.; Koehlin, B.
 CORPORATE SOURCE: Roche Res. Cent., Hoffmann-La Roche Inc., Nutley, NJ,
 07110, USA
 SOURCE: Journal of Pharmaceutical Sciences (1980), 69(11),
 1245-53
 CODEN: JPMSAE; ISSN: 0022-3549
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The metabolic disposition of ¹⁴C-labeled carprofen (I) [53716-49-7] was investigated in rats, dogs, and humans. In dogs and rats, the direct conjugation of I to form an ester glucuronide [76319-13-6] and oxidation to the C-7 (II) [76265-33-3] and the C-8 (III) [70359-64-7] phenols followed by their conjugation represent the major metabolic pathways. Small amounts of the α-hydroxy derivative [70359-62-5] also are formed by these species and are excreted free in the urine. In dogs, biliary secretion predominates, and 70% of an i.v. dose of I is excreted in the feces while 8-15% of the dose is excreted in the urine. In rats, fecal excretion due to biliary secretion varies from 60 to 75%, and urinary excretion accounts for 20-30% of an i.v. dose. In humans, direct conjugation of I represents the only significant pathway of metabolism. Between 65 and 70% of the orally administered I was excreted as the ester glucuronide in the urine, and most of the remaining dose was estimated to be secreted as this metabolite in the bile. Due to enterohepatic circulation, only a fraction of the biliary metabolite was recovered in the feces in humans. Less than 5% of the dose was excreted in human urine as free, intact I. In dogs and humans, plasma levels of I and of total radioactivity exhibit a multiphasic decline. In the human subjects studied, the terminal component declined with a 13-26-h half-life; the terminal half-life was approx. 40 h in dogs.
 IT 76265-34-4
 RL: BIOL (Biological study)
 (as carprofen metabolite, species differences in)
 RN 76265-34-4 CAPLUS


L3 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN β-D-glucopyranosiduronic acid, 7-((1-carboxyethyl)-3-chloro-9H-carbazol-1-yl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1953:6404 CAPLUS
 DOCUMENT NUMBER: 47:6404
 ORIGINAL REFERENCE NO.: 47:1163e-i, 1164a-b
 TITLE: New syntheses of heterocyclic compounds. XVI. Ring closures involving loss of nitrous acid
 AUTHOR(S): Berg, S. S.; Petrov, V.
 CORPORATE SOURCE: May & Baker, Ltd., Dagenham, UK
 SOURCE: Journal of the Chemical Society (1952) 784-7
 CODEN: JCSQAS; ISSN: 0368-1769
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 GI For diagram(s), see printed CA Issue.
 AB cf. C.A. 46, 9564e. 2,4,6-(O₂N)₃C₆H₂Cl (I) (2.5 g.) and 2 g. aminothiazole (II) in 30 ml. C₆H₆, refluxed 5 hrs., give 2.3 g. of a complex, C₁₀H₄N₂S₂C₆H₂O₆N₃Cl, m. 80-110°. 2-Amino-4-methylthiazole (10 g.) in 100 ml. boiling PhMe, treated with 11 g. I in 100 ml. PhMe and refluxed 3 hrs., gives 10.2 g.
 2,3-dihydro-4-methyl-2-picryliminothiazole, crimson, m. 184-5°; ring closure could not be effected. The work of Ochiai and Yanai (C.A. 35,743.6) was repeated (the condensation of I with various pyrimidines) but the high yields for the cyclization could not be reached. 6,8-Dinitro-1,9,11-triazafuorene (500 mg.) in 25 ml. MeOH, reduced (1 hr.) over 100 mg. Pt oxide, gives 200 mg. 6,8-diamino-1,9,11-triazafuorene, green, m. above 300°; 2-Me derivative as the di-HCl salt, pale yellow, m. above 300°. 4,6,8-Triamino-2-methyl-1,9,11-triazafuorene-3-HCl, m. above 300°. 2-Amino-4-methylpyrimidine could not be condensed with 2,4-(O₂N)₂C₆H₃Br. 2,4,6-(O₂N)₃C₆H₂OMe (III) (2.5 g.) and 1 g. 2-aminopyrimidine (IV) in 15 ml. MeOH, refluxed 45 min., give 2.7 g. IV picrate. III (2.4 g.), 0.95 g. IV, 3 g. AcONa, and 40 ml. MeOH, refluxed 5 hrs., give 0.6 g. 2-(N-methylpicrylamino)pyrimidine, yellow, m. 225-6°; 1 g. II yields 700 mg. 2-(N-methylpicrylamino)thiazole, blood red, m. 206-8°. 2-Picrylaminothiazole (1.5 g.), 12 g. III, 1.5 g. AcONa, and 20 ml. MeOH, refluxed 5 hrs., give 200 mg. 2-(N-methylpicrylamino)pyridine, red, m. 242-3°. N-Methylation of carbazole and Ph₂NH could not be effected. 2-Aminopyridine (V) (950 mg.) and 2.6 g. 2,4,6-(O₂N)₃C₆H₂OEt give 500 mg. 2-(N-methylpicrylamino)pyridine, red, m. 234-6°; 950 mg. V and 3 g. [2,4,6-(O₂N)₃C₆H₂]₂O give 100 mg. 2-(N-phenylpicrylamino)pyridine, red, m. 229-31°. 1,2,3,4-Tetrahydro-8-picrylaminothiazole, red, m. 248° (decomposition), results in 13.5 g. yield from 9.3 g. of the NH₂ derivative; ring closure could not be effected by boiling quinoline.
 PhNEt₂ at 200°, hot alc. KOH, or by sublimation at 205-10°/0.03 mm.: PhOH-PhNO₂ at 200° (0.5 hr.) gives a brown amorphous compound, C₁₈H₁₄O₄N₄(?) (m. above 300°). 1-Picrylaminothiazole, crimson, m. 274-5°, 80%: PhNO₂PhOH gives a red-brown amorphous compound, m. above 300°. 5-Chloro-1-methyl-4-nitroglucosamine (8 g.), 5 g. o-H₂NC₆H₄OH, 15 g. AcONa, a trace of KI, and 100 ml. EtOH, refluxed 24 hrs., give 6 g. 1-methyl-4-nitro-5-(o-hydroxyanilino)glucosamine (VII), yellow, m. 222-4° (decomposition), red NaOH solution; 5 g. VI and 40 ml. Et₂NH in 400 ml. EtOH, heated 16 hrs. at 120°, give 1.1 g. (from 1.5 l. AmOH) of blue needles (VII), C₁₀H₈O₃N₃ (?) or C₁₀H₇O₃N₃, m. above 310°; this may be the free-radical azyl (VIII) or the azhydri (IX) structure, of which the latter is preferred. VII (4 g.) in 200 ml. concentrated H₂SO₄, treated at 10-20° with 4 g. Zn, gives a pink compound [C₁₀H₇O₃N₃ (7)], m. 250-5°, which is very rapidly oxidized to VII.

L3 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 IT 854825-92-6P, Carbazole, 1-(2,4,6-trinitroanilino)-
 RL: PREP (Preparation)
 (preparation of)
 RN 854825-92-6 CAPLUS
 CN Carbazole, 1-(2,4,6-trinitroanilino)- (5CI) (CA INDEX NAME)





L3 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1931:6290 CAPLUS
DOCUMENT NUMBER: 25:6290
ORIGINAL REFERENCE NO.: 25:716h-i
TITLE: 1-Aminocarbazole
INVENTOR(S): Muth, Friedrich; Schmelzer, Albert
PATENT ASSIGNEE(S): I. G. Farbenindustrie AG
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	DE 507797		19270314	DE	
AB	1-Aminocarbazole and deriva. are prepared by first introducing the SO ₃ H group into the carbazole mol., then introducing the NO ₂ group into the 1-position, reducing it to the NH ₂ group, and finally removing the SO ₃ H group if desired. Examples describe the preparation of 1-nitrocarbazole-3,6,8-sulfonic acid, 1-aminocarbazole-3,6,8-sulfonic acid, 1-aminocarbazole and 1-phenylaminocarbazole.				
IT	859084-79-0P, Carbazole, 1-anilino- RL: PREP (Preparation) (preparation of)				
RN	859084-79-0 CAPLUS				
CN	INDEX NAME NOT YET ASSIGNED				



=>

Uploading C:\Program Files\Stnexp\Queries\10560013\1b.str



chain nodes :

16 17

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13

chain bonds :

13-16 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 8-13 10-11 11-12 12-13

exact/norm bonds :

5-7 6-9 7-8 7-10 8-9 8-13 11-12 13-16 16-17

exact bonds :

10-11 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:NH,O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 16:CLASS 17:Atom

Generic attributes :

17:
Saturation : Unsaturated


L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4

STR



G1 NH,O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l4 full sub=l2

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SUBSET SEARCH INITIATED 12:31:44 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 253 TO ITERATE

100.0% PROCESSED 253 ITERATIONS (3 INCOMPLETE) 98 ANSWERS
SEARCH TIME: 00.00.01

L5 98 SEA SUB=L2 SSS FUL L4

SUBSET IS IGNORED AS A SCOPE FOR THIS SEARCH

L6 10 L5

=> d ibib abs hitstr 1-10

L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1207231 CAPLUS

DOCUMENT NUMBER: 145:489114

TITLE:

Preparation of carbazoles and related compounds for treatment of dengue fever, yellow fever, west nile virus, and hepatitis C virus infection.

INVENTOR(S):

Gudmundsson, Kristjan

PATENT ASSIGNEE(S):

Smithkline Beecham Corporation, USA

SOURCE:

PCT Int. Appl., 59pp.

CODEN: BXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006121467	A2	20061116	WO 2005-US41091	20051114
WO 2006121467	A3	20070125		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-630166P P 20041122

OTHER SOURCE(S):

MARPAT 145:489114


GI




AB Title compds. [I; n = 0-2; X = NH, O, S, SO, SO₂; R, R₁ = halo, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aryloxy, arylamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, cyano, NO₂, N₃, etc.;

P, q = 0-5; A = aryl, heteroaryl], were prepared for the treatment of infection due to flaviviruses, pestiviruses, and hepaciviruses. Thus, 6-chloro-N-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine (preparation outlined)


L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-16-4 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 812649-17-5 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 812649-18-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-N-(4-fluorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

showed anti-HCV activity with IC₅₀ = 5 nM.

812649-13-1P 812649-14-2P 812649-15-3P

812649-16-4P 812649-17-5P 812649-18-6P

812649-19-7P 812649-20-0P 812649-21-1P

812649-22-2P 812649-23-3P 812649-24-4P

812649-25-5P 812649-26-6P 812649-27-7P

812649-28-8P 812649-29-9P 812649-30-2P

812649-31-3P 812649-32-4P 812649-33-5P

812649-34-6P 812649-35-7P 812649-36-8P

812649-37-9P 812649-38-0P 812649-39-1P

812649-41-5P 812649-42-6P 812649-44-8P

812649-45-9P 812649-46-0P 812649-47-1P

812649-48-2P 812649-49-3P 812649-50-6P

812649-51-7P 812649-52-8P 812649-53-9P

812649-17-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

[preparation of carbazoles and related compds. for treatment of dengue fever, yellow fever, west nile virus, and hepatitis C virus infection]

RN 812649-13-1 CAPLUS


CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)

INDEX NAME)



RN 812649-14-2 CAPLUS

CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 812649-15-3 CAPLUS

CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-19-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 812649-20-0 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 812649-21-1 CAPLUS

L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI)
 (CA INDEX NAME)




RN 812649-22-2 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
 (CA INDEX NAME)




RN 812649-23-3 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 812649-27-7 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-28-8 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



● HCl


RN 812649-29-9 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(5-propyl-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 812649-24-4 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-25-5 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-26-6 CAPLUS


L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)



RN 812649-30-2 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methyl-N-2-pyrimidinyl- (9CI)
 (CA INDEX NAME)




RN 812649-31-3 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methoxy-N-2-pyrimidinyl- (9CI)
 (CA INDEX NAME)




RN 812649-32-4 CAPLUS
 CN 1H-Carbazol-1-amine, N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 812649-33-5 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 812649-34-6 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 812649-37-9 CAPLUS
 CN 1H-Carbazol-1-amine, N-2-benzothiazolyl-6-bromo-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 812649-38-0 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 812649-39-1 CAPLUS
 CN Cyclohept[b]indol-6-amine, 2-bromo-5,6,7,8,9,10-hexahydro-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 812649-41-5 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methyl-N-2-pyrimidinyl-, monohydrochloride (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-35-7 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-tetrahydro-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 812649-36-8 CAPLUS
 CN 3-Pyridinecarbonitrile, 6-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]- (9CI) (CA INDEX NAME)




L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 812649-42-6 CAPLUS
 CN 1H-Carbazole-6-carboxylic acid, 2,3,4,9-tetrahydro-1-(phenylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 812649-44-8 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl-6-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 812649-45-9 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-46-0 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(3-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 812649-47-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 812649-48-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-1H-indol-5-yl- (9CI)
(CA INDEX NAME)


L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-52-8 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 812649-53-9 CAPLUS
CN 1H-Carbazole, 6-bromo-1-(4-fluorophenoxy)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 814255-17-9 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)amino]- (9CI)
(CA INDEX NAME)


L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-49-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(2-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 812649-50-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)



RN 812649-51-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)

L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L6 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2006:1207230 CAPLUS
 DOCUMENT NUMBER: 145:500040
 TITLE: Treatment of prophylaxis of Flaviviridae viruses
 using substituted 2,3,4,9-tetrahydro-1H-carbazoles and related compounds
 INVENTOR(S): Gudmundsson, Kristjan
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 70pp.
 CODEN: PIXXDE
 Patent
 DOCUMENT TYPE: English
 LANGUAGE:
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006121466	A2	20061116	2005-US41090	20051114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2004-629906P P 20041122

OTHER SOURCE(S): MARPAT 145:500040
 GI



AB The present invention relates to 2,3,4,9-tetrahydro-1H-carbazoles and related compds. (shown as I; variables defined below; e.g. N-benzyl-2,3,4,9-tetrahydrocarbazol-1-amine hydrochloride) that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compds. useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV. For I: n = 0-2; R is H or alkyl; X is NR2, O, or S(O)m; each R1 = H, halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, Ay, -NHR10Ay, Het,


L6 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 -NHR10Het, -NHR10Het, -OR2, -OAY, -OHet, -R10OR2, -NR2R3, -NR2Ay, -R10NR2R3

et al.; Y is (un)substituted alkylene, cycloalkylene, alkenylene, cycloalkenylene, or alkynylene; d = 0-1; Z is -R2, -OR2, -C(O)R2, -C(O)2R2, -S(O)mR2, -C(O)NR2R3, -Het, or Ay, provided when d is 0, then Z is not -Het or -Ay; each m = 0-2; each R10 = alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene; p = 0-4; each of R2 and R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, -R10OH, -R10(OR10)m, and -R10NR5R6; w = 1-10; each of R5 and R6 = alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl; Ay = (un)substituted

aryl:
 Het = (un)substituted 5- or 6-membered heterocyclyl or heteroaryl group; addnl. details are given in the claims. Inhibition of HCV activity was measure for 3 examples of I, e.g. IC50 = 8 nM for (1R)-6-Bromo-N-((1S)-1-phenylethyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride. Although the methods of prepn. are not claimed, prepn. and/or characterization data for approx. 70 examples of I are included. For example, N-benzyl-2,3,4,9-tetrahydrocarbazol-1-amine hydrochloride was prepd. (35 % yield) by addn. of sodium triacetoxyborohydride, acetic acid and benzylamine to a dichloroethane soln. of 2,3,4,9-tetrahydro-1H-carbazol-1-one, which was prepd. in 2 steps from 4-chloroaniline, NaNO2 and 2-(hydroxymethylene)cyclohexanone in which the intermediate cyclohexane-1,2-dione (4-chlorophenyl)hydrazone was cyclized.

IT 847988-07-2, 6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process)
 viruses (chromatog. resolution; treatment or prophylaxis of Flaviviridae

using substituted 2,3,4,9-tetrahydro-1H-carbazoles and related compds.)
 RN 847988-07-2 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




IT 847988-06-1P, (1R)-6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride 847988-08-3P,

(1S)-6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

L6 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 PREP (Preparation); USES (Uses)
 (drug candidate; treatment or prophylaxis of Flaviviridae viruses
 using substituted 2,3,4,9-tetrahydro-1H-carbazoles and related compds.)
 RN 847988-06-1 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 847988-08-3 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 847988-00-5P, N-(2,3-Dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride 847988-24-3P, N-(2,3-Dihydro-1H-inden-2-yl)-6-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride 847988-48-1P, 7-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine monohydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; treatment or prophylaxis of Flaviviridae viruses


using

L6 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 substituted 2,3,4,9-tetrahydro-1H-carbazoles and related compds.)
 RN 847988-00-5 CAPLUS
 CN 1H-Carbazol-1-amine, N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 847988-24-3 CAPLUS
 CN 1H-Carbazol-1-amine, N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 847988-48-1 CAPLUS
 CN 1H-Carbazol-1-amine, 7-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:608619 CAPLUS
 DOCUMENT NUMBER: 145:83213
 TITLE: Preparation of tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
 INVENTOR(S): Lennox, William Joseph; Qi, Hongyan; Lee, Duck-Hyung; Choi, Soongyu; Moon, Young-Choon
 PATENT ASSIGNEE(S): PTC Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006065480	A2	20060622	WO 2005-US42483	20051123
WO 2006065480	A3	20060803		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-629889P P 20041123
 US 2004-633738P P 20041206
 US 2004-639283P P 20041227

OTHER SOURCE(S): MARPAT 145:83213
 GI

L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The present invention relates to methods, compds., and compns. for inhibiting angiogenesis. More particularly, the present invention relates to methods, compds., and compns. for inhibiting VEGF production. The title compds. I [X = NR9R10, N(alkyl)C(O)aryl, H, etc. (wherein R9, R10 = H, alkyl, aryl, etc.; or NR9R10 = mono- or bicyclic heterocyclic ring); R1-R3 = H, OH, alkyl (wherein R1 may optionally form (un)substituted 5-11 membered mono- or bi-heterocyclic ring with X); n = 0-2; R4-R7 = H, OH, alkyl, etc.; W = N, O, S; R8 = H, alkyl, cycloalkyl, etc.; with the provision] were prepared. Thus, reacting amine II with 2,3-diformylthiophene followed by treating the intermediate lactam III with LAH in THF afforded IV which showed EC50 of <0.01 μM in an assay evaluating the ability of compds. I to modulate hypoxia-inducible endogenous VEGF expression.

IT 812649-13-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control)


RN 812649-13-1 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 812649-16-4P 812649-17-5P 812649-20-0P
 812649-21-1P 812649-22-2P 812649-46-0P
 812649-47-1P 812649-49-3P 812649-50-6P
 812649-51-7P 812649-52-8P 812649-53-9P
 814255-12-4P 814255-18-0P 893409-63-7P
 893409-67-1P 893409-69-3P 893409-71-7P
 893409-75-1P 893409-76-2P 893409-77-3P
 893409-79-5P 893409-83-1P 893409-85-3P
 893409-86-4P 893409-87-5P 893409-88-6P
 893409-93-3P 893409-96-6P 893409-97-7P
 893409-99-9P 893410-02-1P 893410-06-5P
 893410-08-7P 893410-10-1P 893410-32-7P
 893410-61-2P 893410-62-3P 893410-63-4P
 893410-64-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control)

RN 812649-16-4 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 812649-17-5 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-20-0 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 812649-21-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)


L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 812649-47-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)



RN 812649-49-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(2-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 812649-50-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 812649-51-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)


L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-22-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(4-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 812649-46-0 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(3-methoxyphenyl)- (9CI)
(CA INDEX NAME)




L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-52-8 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 812649-53-9 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-1-(4-fluorophenoxy)-2,3,4,9-tetrahydro- (9CI)
(CA INDEX NAME)




RN 814255-12-4 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-2-pyrimidinyl- (9CI)
(CA INDEX NAME)


L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 814255-18-0 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 893409-63-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 893409-67-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-(1-methylethyl)phenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893409-76-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 893409-77-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3-chlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 893409-79-5 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3,5-dimethylphenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893409-69-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 893409-71-7 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 893409-75-1 CAPLUS
CN 1H-Carbazol-1-amine, N-1,3-benzodioxol-5-yl-6-bromo-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893409-83-1 CAPLUS
CN 1H-Carbazol-1-amine, N-[1,1'-biphenyl]-4-yl-6-bromo-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 893409-85-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-pyrazinyl- (9CI) (CA INDEX NAME)




RN 893409-86-4 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-difluorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893409-87-5 CAPLUS
CN Cyclohept[b]indol-6-amine, 2-bromo-5,6,7,8,9,10-hexahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 893409-88-6 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl-6-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 893409-93-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-[(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 893409-99-9 CAPLUS
CN 1H-Carbazol-1-amine, 7-bromo-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)



RN 893410-02-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-3-isoxazolyl- (9CI) (CA INDEX NAME)




RN 893410-06-5 CAPLUS
CN Acetamide, N-[4-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 893410-08-7 CAPLUS
CN 1,4-Benzenediamine, N'-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N,N-dimethyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 893409-96-6 CAPLUS
CN 1H-Carbazol-1-amine, 5-bromo-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 893409-97-7 CAPLUS
CN Benzonitrile, 4-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]- (9CI) (CA INDEX NAME)




L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893410-10-1 CAPLUS
CN Benzeneethanol, 3-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]- (9CI) (CA INDEX NAME)




RN 893410-32-7 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-1H-pyrrol-1-yl- (9CI) (CA INDEX NAME)




RN 893410-61-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-[(4-trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893410-62-3 CAPLUS
CN 1H-Carbazol-1-amine, N-(4-chlorophenyl)-2,3,4,9-tetrahydro-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 893410-63-4 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-(4-methoxyphenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:128535 CAPLUS
DOCUMENT NUMBER: 144:369846
TITLE: Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists
AUTHOR(S): Di Fabio, Romano; Giovannini, Riccardo; Bertani, Barbara; Borriello, Manuela; Bozzoli, Andrea; Donati, Daniele; Falchi, Alessandro; Ghirlanda, Damiano; Leslie, Colin P.; Pecunioso, Angelo; Rumboldt, Giovanna; Spada, Simone
CORPORATE SOURCE: GlaxoSmithKline Medicines Research Centre, Verona, 37135, Italy
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1749-1752
CODEN: BMCLES; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:369846
GI




AB The SAR of a new series of tetrahydrocarbazole derivs. I (R1 = Me, 3-(1-piperidinyl)propyl, piperidin-4-ylmethyl, etc.; R2 = H, 4-morpholinyl, 1-piperidinyl, 4-methyl-1-piperazinyl, etc.) is evaluated: the appropriate decoration of this template led to the identification of

a new class of NPY-1 antagonists showing good in vitro potency and a promising in vivo pharmacokinetic profile in rat.
IT 882033-76-3P 882033-77-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and SAR of amino(chlorophenoxy)tetrahydrocarbazolones as


NPY-1 antagonists)
RN 882033-76-3 CAPLUS
CN 1H-Carbazole, 1-(4-chlorophenoxy)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 893410-64-5 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-(trifluoromethyl)-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 882033-77-4 CAPLUS
CN 4H-Carbazol-4-one, 1-(4-chlorophenoxy)-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L6 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:444285 CAPLUS
 DOCUMENT NUMBER: 143:162008
 TITLE: Effects of fluorination on electronic and excited states of fused zinc oligoporphyrins
 AUTHOR(S): Yamaguchi, Yoichi
 CORPORATE SOURCE: KRI, Kyoto, 600-8813, Japan
 SOURCE: Journal of Chemical Physics (2005), 122(18), 184702/1-184702/10
 CODEN: JCPSA6; ISSN: 0021-9606
 PUBLISHER: American Institute of Physics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB D. functional theory (DFT) has been applied to study the effect of fluorination on the electronic and excited states of fused zinc oligoporphyrins in the search for new functionalizing materials, such as n-type organic semiconductors. The excitation spectra of meso-tetrafluoro, β -octafluoro, and perfluoro zinc porphyrins, and their triply meso-meso-, β - β , and β - β -linked fluorinated zinc oligoporphyrins were systematically examined using the time-dependent DFT method. The effect of the perfluorination on the zinc porphyrin (ZnP) causes the maximum 1.12 eV and 1.42 eV drops for the highest occupied and LUMO (HOMO and LUMO, resp.) levels, resp. The electronic and excitation features of the fluorinated ZnPs are almost similar to the unfluorinated ones. However, the large antibonding contribution of the meso-fluorines disturbs the stabilization of the HOMO, resulting in a more effective reduction of both the HOMO-LUMO gaps and the lowest Q excitation energies with the increasing number of porphyrins compared to the unfluorination and the


other types of fluorinations. It is found that the infinite fused fluorinated ZnP tapes with narrow gap (≈ 0.1 eV-0.2 eV) as predicted by using the periodic-DFT level are slightly inferior to the near-zero gap semimetallic unfluorinated ZnP tape as a conducting mol. wire. The combination of the condensation and the meso- and/or β -fluorination of ZnP can finely tune the LUMO level to the Fermi level of the electrodes for fabrication of n-type conducting materials. The fused fluoro-oligoporphyrins may then become new n-type organic semiconductors, provided they are well crystallized with a high electron mobility, such as the recently synthesized perfluoropentacene.

IT 859507-60-1
 RL: PEP (Physical, engineering or chemical process); PRP (Properties);

PYP (Physical process); PROC (Process)
 (comparison: fluorination effect on electronic and excited states of fused zinc oligoporphyrins in relation to)

RN 859507-60-1 CAPLUS
 CN Poly(5,15-difluoro-21H,23H-porphine-2,18,20:8,10,12-hexayl- κ N21, κ N22, κ N23, κ N24 (SP-4-1)-zinc complex) (9CI)
 (CA INDEX NAME)

L6 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 61, THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L6 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:232610 CAPLUS
 DOCUMENT NUMBER: 142:316689
 TITLE: Preparation of novel cycloalkyl(b) condensed indoles for treating human papillomaviruses
 INVENTOR(S): Boggs, Sharon Davis; Catalano, John G.; Gudmundsson, Kristjan S.; D'Aurora Richardson, Leah; Sebahar, Paul Richard
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021245	A1	20050317	WO 2004-US17982	20040607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1658068	A1	20060524	EP 2004-754553	20040607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2007503434	T	20070222	JP 2006-524621	20040607
US 2006281804	A1	20061214	US 2006-569524	20060224
PRIORITY APPL. INFO.: US 2003-497845P			US 2003-497845P	20030826
			WO 2004-US17982	20040607

OTHER SOURCE(S): MARPAT 142:316689
 GI




AB The present invention relates to cycloalkyl(b) condensed indoles (shown as I: variables defined below; e.g. 6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-

L6 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 amine), including administration of pharmaceutically acceptable salts, solvates, and physiol. functional derivs. thereof, that are useful in the treatment of human papillomaviruses (HPVs), and also to the methods for the making and use of such compds. HPV inhibition values for 56 examples of I are reported. For I: n = 0-2; R is H or alkyl; X is NR2, O, or S(O)m; each R1 = H, halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, R10cycloalkyl, Ay, NR10ay, Het, NHHet, NR10Het, OR2, ORy, OHet, R10OR2, NR2R3, NR2Ay, R10NR2R3, R10NR2Ay, R10C(O)R2, C(O)R2, CO2R2, R10CO2R2, C(O)NR2R3, C(O)Ay, C(O)NR2Ay, C(O)Het, C(O)NR10Het, R10C(O)NR2R3, C(S)NR2R3, R10C(S)NR2R3, R10NHC(NH)NR2R3, C(NH)NR2R3, R10C(NH)NR2R3, S(O)2NR2R3, S(O)2NR2Ay, R10SO2NHCOR2, ROSO2NR2R3, R10SO2R2, S(O)NR2, cyano, nitro, or azido. Y is (un)substituted alkylene, (un)substituted cycloalkylene, (un)substituted alkenylene, (un)substituted cycloalkenylene, or (un)substituted alkynylene; d = 0-1; Z is R2, OR2, C(O)R2, C(O)R2R2, S(O)NR2, C(O)NR2R3, Het, or Ay, provided when d is 0, then Z is not Het or Ay; each m = 0-2; each R10 = alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene; p = 0-4; each of R2 and R3 H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, R10cycloalkyl, R10OH, R10(OR10)w, and R10NR5R6; w = 1-10; each of R5 and R6 = alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl; Ay = (un)substituted aryl; Het = (un)substituted 5- or 6-membered heterocyclyl or heteroaryl. Although the methods of prepn.

are not claimed, approx. 70 example prepn. are included. For example, 6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-amine was prepd. (52 %) from 6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-one, NH4OAc, and NaBH3CN in MeOH; the ketone was prepd. (88 %) by cyclization of cyclohexane-1,2-dione (4-chlorophenyl)hydrazone, which was prepd. (49 %) from the diazonium salt of 4-chloroaniline and 2-(hydroxymethylene)cyclohexanone.

IT 847988-07-2, 6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
 (chromatog. resolution: preparation of novel cycloalkyl(b) condensed indoles for treating human papillomaviruses)

RN 847988-07-2 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




IT 847988-06-1P, (1R)-6-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 847988-08-3P,

L6 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1-amine hydrochloride
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of novel cycloalkyl[b] condensed indoles for treating human papillomaviruses)

RN 847988-06-1 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 847988-08-3 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 847988-00-5P, N-(2,3-Dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride 847988-24-3P,
 N-(2,3-Dihydro-1H-inden-2-yl)-6-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-

L6 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L6 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 amine hydrochloride 847988-48-1P, 7-Bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of novel cycloalkyl[b] condensed indoles for treating human papillomaviruses)

RN 847988-00-5 CAPLUS
 CN 1H-Carbazol-1-amine, N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 847988-24-3 CAPLUS
 CN 1H-Carbazol-1-amine, N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 847988-48-1 CAPLUS
 CN 1H-Carbazol-1-amine, 7-bromo-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:1127334 CAPLUS
 DOCUMENT NUMBER: 142:74445
 TITLE: Preparation of tetrahydrocarbazole derivatives as human papillomaviruses inhibitors
 INVENTOR(S): Boggs, Sharon Davis; Gudmundsson, Kristjan S.; Richardson, Leah D'Aurora; Sebahar, Paul Richard
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 69 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200410999	A1	20041223	WO 2004-US17660	20040607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TW, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004247676	A1	20041223	AU 2004-247676	20040607
CA 2528321	A1	20041223	CA 2004-2528321	20040607
EP 1654228	A1	20060510	EP 2004-776279	20040607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011085	A	20060725	BR 2004-11085	20040607
CN 1832921	A	20060913	CN 2004-80022227	20040607
JP 2007501284	T	20070125	JP 2006-533561	20040607
NO 2005005741	A	20060106	NO 2005-5741	20051205
US 2006161002	A1	20060720	US 2005-560013	20051208
			US 2003-477251P	20030610
			US 2003-497823P	20030826
			WO 2004-US17660	20040607

OTHER SOURCE(S): MARPAT 142:74445
 GI




AB Title compds. represented by the formula I (wherein R, R1 = independently

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
halo(alkyl), (cyclo)alkenyl, (amino)aryl, etc.; X = NH, O or SO₂; m =
0-2;
n = 0-2; p, q = independently 0-5; A = (hetero)aryl; and pharmaceutically
acceptable salts, solvates, and physiol. functional derivs. thereof were
prepd. as human papillomaviruses (HPV) inhibitors. For example, II was
given in a multi-step synthesis starting from the reaction of
4-chloroaniline with 2-(hydroxymethylene)cyclohexanone. II showed
inhibition of HPV 16 with IC₅₀ values of 10 nM in W-12 cellular assay.
Thus, I and their pharmaceutical compns. are useful for the treatment or
prophylaxis of conditions or disorders due to HPV infection, such as
warts
and cancers (no data).
IT 812649-13-1P, 6-Bromo-N-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-
amine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetrahydrocarbazole derivs. as human papilloma viruses
inhibitors)
RN 812649-13-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA
INDEX NAME)




IT 812649-14-2P, 6-Bromo-N-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-
amine hydrochloride 812649-15-3P, 6-Chloro-N-phenyl-2,3,4,9-
tetrahydro-1H-carbazol-1-amine 812649-16-4P,
6-Chloro-N-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-17-5P, 6-Chloro-N-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-
carbazol-1-amine 812649-18-6P, 6-Chloro-N-(4-fluorophenyl)-
2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-19-7P,
6-Chloro-N-(4-methylphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-20-0P, 6-Bromo-N-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-
carbazol-1-amine 812649-21-1P, 6-Bromo-N-(4-chlorophenyl)-
2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-22-2P,
6-Bromo-N-(4-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-23-3P, 6-Bromo-N-(pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-
carbazol-1-amine hydrochloride 812649-24-4P,
6-Chloro-N-(pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-25-5P, 6-Chloro-N-(4,6-dimethoxypyrimidin-2-yl)-2,3,4,9-
tetrahydro-1H-carbazol-1-amine 812649-26-6P,
6-Chloro-N-(4-methylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-27-7P, 6-Chloro-N-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-
tetrahydro-1H-carbazol-1-amine 812649-28-8P,
6-Bromo-N-(pyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




• HCl

RN 812649-15-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA
INDEX NAME)



RN 812649-16-4 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 812649-17-5 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-N-(4-chlorophenyl)-2,3,4,9-tetrahydro-
(9CI) (CA INDEX NAME)


L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hydrochloride 812649-29-9P, 6-Bromo-N-(5-propylpyrimidin-2-yl)-
2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-30-2P,
6-Methyl-N-(pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-31-3P, 6-Methoxy-N-(pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-
carbazol-1-amine 812649-32-4P, N-(4,6-Dimethoxypyrimidin-2-yl)-6-
methyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride
812649-33-5P, 6-Bromo-N-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-
tetrahydro-1H-carbazol-1-amine hydrochloride 812649-34-6P,
6-Bromo-N-[5-(trifluoromethyl)pyrimidin-2-yl]-2,3,4,9-tetrahydro-1H-
carbazol-1-amine 812649-35-7P, 6-Bromo-N-[5-
(trifluoromethyl)pyrimidin-2-yl]-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-36-8P, 6-[(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-
yl)amino]nicotinonitrile 812649-37-9P, N-(1,3-Benzothiazol-2-yl)-
6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-38-0P,
N-Pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-39-1P, 2-Bromo-N-(pyrimidin-2-yl)-5,6,7,8,9,10-
hexahydrocyclohepta[b]indol-6-amine 812649-41-5P,
6-Methyl-N-(pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
hydrochloride 812649-42-6P, Methyl 1-anilino-2,3,4,9-tetrahydro-
1H-carbazole-6-carboxylate 812649-43-7P, 6-[(6-Methyl-2,3,4,9-
tetrahydro-1H-carbazol-1-yl)amino]nicotinonitrile hydrochloride
812649-44-8P, N-Phenyl-6-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-
carbazol-1-amine hydrochloride 812649-45-9P,
N-Phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-46-0P,
6-Bromo-N-(3-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-47-1P, 6-Bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro-1H-
carbazol-1-amine 812649-48-2P, 6-Bromo-N-(1H-indol-5-yl)-2,3,4,9-
tetrahydro-1H-carbazol-1-amine 812649-49-3P,
6-Bromo-N-(2-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-50-6P, 6-Bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro-1H-
carbazol-1-amine 812649-51-7P, 6-Bromo-N-(2-fluorophenyl)-
2,3,4,9-tetrahydro-1H-carbazol-1-amine 812649-52-8P,
6-Bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
812649-53-9P, 6-Bromo-1-(4-fluorophenoxy)-2,3,4,9-tetrahydro-1H-
carbazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(prepn. of tetrahydrocarbazole derivs. as human papilloma viruses
inhibitors)

RN 812649-14-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-phenyl-
monohydrochloride (9CI) (CA INDEX NAME)


L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-18-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-N-(4-fluorophenyl)-2,3,4,9-tetrahydro-
(9CI) (CA INDEX NAME)




RN 812649-19-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 812649-20-0 CAPLUS

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(4-methoxyphenyl)-
 (9CI) (CA INDEX NAME)




RN 812649-21-1 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4-chlorophenyl)-2,3,4,9-tetrahydro- (9CI)
 (CA INDEX NAME)




RN 812649-22-2 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-N-(4-fluorophenyl)-2,3,4,9-tetrahydro- (9CI)
 (CA INDEX NAME)

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 812649-25-5 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 812649-26-6 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 812649-27-7 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-28-8 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-2-pyridinyl-,
 monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-23-3 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-2-pyrimidinyl-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 812649-24-4 CAPLUS
 CN 1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-2-pyrimidinyl- (9CI)
 (CA INDEX NAME)




L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 812649-29-9 CAPLUS
 CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(5-propyl-2-pyrimidinyl)-
 (9CI) (CA INDEX NAME)




RN 812649-30-2 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methyl-N-2-pyrimidinyl- (9CI)
 (CA INDEX NAME)




RN 812649-31-3 CAPLUS
 CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methoxy-N-2-pyrimidinyl- (9CI)

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-32-4 CAPLUS
CN 1H-Carbazol-1-amine, N-(4,6-dimethoxy-2-pyrimidinyl)-2,3,4,9-tetrahydro-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 812649-33-5 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(4,6-dimethyl-2-pyrimidinyl)-2,3,4,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 812649-34-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(5-(trifluoromethyl)-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 812649-35-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(5-(trifluoromethyl)-2-pyrimidinyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-36-8 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]- (9CI) (CA INDEX NAME)




RN 812649-37-9 CAPLUS
CN 1H-Carbazol-1-amine, N-2-benzothiazolyl-6-bromo-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-38-0 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-(phenylamino)-, methyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-39-1 CAPLUS
CN Cyclohept[b]indol-6-amine, 2-bromo-5,6,7,8,9,10-hexahydro-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 812649-41-5 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-6-methyl-N-2-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 812649-42-6 CAPLUS
CN 1H-Carbazol-6-carboxylic acid, 2,3,4,9-tetrahydro-1-(phenylamino)-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 812649-43-7 CAPLUS
CN 3-Pyridinecarbonitrile, 6-((2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)amino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 812649-44-8 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl-6-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 812649-45-9 CAPLUS
CN 1H-Carbazol-1-amine, 2,3,4,9-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)


L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-49-3 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 812649-50-6 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-51-7 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(2-fluorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)


L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-46-0 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 812649-47-1 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 812649-48-2 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-2,3,4,9-tetrahydro-N-1H-indol-5-yl- (9CI) (CA INDEX NAME)


L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 812649-52-8 CAPLUS
CN 1H-Carbazol-1-amine, 6-bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 812649-53-9 CAPLUS
CN 1H-Carbazole, 6-bromo-1-(4-fluorophenoxy)-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

X = 0

L6 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:76528 CAPLUS
 DOCUMENT NUMBER: 139:371731
 TITLE: Photophysical Properties of Directly Linked Linear Porphyrin Arrays
 AUTHOR(S): Kim, Dongho; Osuka, Atsuhiko
 CORPORATE SOURCE: National Creative Research Initiatives Center for Ultrafast Optical Characteristics Control and Department of Chemistry, Yonsei University, Seoul, 120-749, S. Korea
 SOURCE: Journal of Physical Chemistry A (2003), 107(42), 8791-8816
 CODEN: JPACAFH; ISSN: 1089-5639
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A variety of porphyrin arrays connected by diverse linkers have been envisaged and prepared for the applications in mol. photonics and electronics. From a viewpoint of operational requirements, the porphyrin arrays should have the very regular pigment arrangements which allow a facile light energy or charge flow along the arrays but do not result in the alteration of individual properties of the constituent pigments leading to formation of so-called energy or charge sink. In these respects, the directly coupled (orthogonal and fused) porphyrin arrays without any linkers are ideal, because the conformational heterogeneity mainly arising from a dihedral angle distribution between the neighboring porphyrin moieties should be minimized. In addition, the electronic effect of the linker can be disregarded in design strategy of mol. photonic devices, because the linker can also be considered as a transmission element in electronic communication. Considering these features, these types (orthogonal vs fused) of porphyrin arrays would be one of the most suitable synthetic mol. modules for the realization of mol. photonic and electronic devices. To unveil the functionalities of various porphyrin arrays, starting from the dihedral angle dependence on the photophys. properties of the porphyrin dimers, we have extended our knowledge to longer orthogonal and fused porphyrin arrays. Overall, the regularly arranged porphyrin arrays with ample electronic interactions will be promising in the applications such as mol. wires, sensors, optical nonlinear materials, and so on.
 IT 486445-26-5
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
 RN (photophys. properties of directly linked linear porphyrin arrays)
 CN 486445-26-5 CAPLUS
 Poly[[5,15-bis(4-(1,1-dimethyltridecyl)phenyl)-21H,23H-porphine-2,20,18:8,10,12-hexayl-κN21,κN22,κN23,κN24] zinc complex] (9CI) (CA INDEX NAME)

L6 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

REFERENCE COUNT: 121 THERE ARE 121 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L6 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:870385 CAPLUS
 DOCUMENT NUMBER: 138:114936
 TITLE: Photophysical properties of porphyrin tapes
 AUTHOR(S): Cho, Hyun Sun; Jeong, Dae Hong; Cho, Sung; Kim, Dongho; Matsuzaki, Yoichi; Tanaka, Kazuyoshi; Tsuda, Akihiko; Osuka, Atsuhiko
 CORPORATE SOURCE: Center for Ultrafast Optical Characteristics Control and Department of Chemistry, Yonsei University, Seoul, 120-749, S. Korea
 SOURCE: Journal of the American Chemical Society (2002), 124(49), 14642-14654
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The novel fused Zn(II) porphyrin arrays (Tn, porphyrin tapes) in which the porphyrin macrocycles are triply linked at meso-meso, β-β, β-β positions have been investigated by steady-state and time-resolved spectroscopic measurements along with theor. MO calcs.
 The absorption spectra of the porphyrin tapes show a systematic downshift to the IR region as the number of porphyrin pigments increases in the arrays. The fused porphyrin arrays exhibit a rapid formation of the lowest excited states (for T2, .apprx.500 fs) via fast internal conversion processes upon photoexcitation at 400 nm (Soret bands), which is much faster than the internal conversion process of .apprx.1.2 ps observed for a monomeric Zn(II) porphyrin. The relaxation dynamics of the lowest excited states of the porphyrin tapes were accelerated from .apprx.4.5 ps for the T2 dimer to .apprx.0.3 ps for the T6 hexamer as the number of porphyrin units increases, being explained well by the energy gap law. The overall photophys. properties of the porphyrin tapes were observed to be in a sharp contrast to those of the orthogonal porphyrin arrays. The PPP-SCI calculated charge-transfer probability indicates that the lowest excited state of the porphyrin tapes (Tn) resembles a Wannier-type exciton closely, whereas the lowest excited state of the directly linked porphyrin arrays can be considered as a Frenkel-type exciton. Conclusively, these unique photophys. properties of the porphyrin tapes have aroused much interest in the fundamental photophysics of large flat organic mols. as well as in the possible applications as elec. wires, IR sensors, and nonlinear optical materials.
 IT 486445-26-5
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
 RN (photophys. properties of fused zinc porphyrin studied by steady-state and time-resolved spectroscopy and theor. MO calcs.)
 CN 486445-26-5 CAPLUS

L6 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Poly[[5,15-bis(4-(1,1-dimethyltridecyl)phenyl)-21H,23H-porphine-2,20,18:8,10,12-hexayl-κN21,κN22,κN23,κN24] zinc complex] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L6 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1988:493909 CAPLUS
 DOCUMENT NUMBER: 109:93909
 TITLE: The effect of heteroatomic substitutions on the band gap of polyacetylene and poly(p-phenylene) derivatives
 AUTHOR(S): Lee, Yong Sok; Kertesz, Miklos
 CORPORATE SOURCE: Dep. Chem., Georgetown Univ., Washington, DC, 20057, USA
 SOURCE: Journal of Chemical Physics (1988), 88(4), 2609-17
 CODEN: JCPSA6; ISSN: 0021-9606
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The electronic structures of poly(p-phenylene) (I), polyacetylene (II), and their derivs. with small energy gaps were studied by the Hueckel and MNDO crystal orbital methods. The effect of nuclear relaxation and heteroat. substitution on the energy gaps (Eg) were taken into account by complete geometry optimization using periodic boundary conditions as opposed to earlier cluster-based calcs. Calcs. were done on: polypyrrole (III), polythiophene (IV), poly(isothianaphthene) (V), poly(5,5'-bithiophenemethenyl) (VI), and poly(5,5'-bipyrrolemethenyl) (VII). Energetics and band gaps for the 2 isomeric forms, the quinoid and aromatic structures of III and IV are discussed and critical compared with previous calcs. PMO theory is invoked to explain the narrower Eg for V, VI, and VII relative to that of II. Calcs. for I derivs., (polybenzo[b]thiophene, polybenzo[b,f]thieno[3,4-c]thiophene, and polybenzo[b,f]pyrrolo[3,4-c]pyrrole) show that the Eg of some of these polymers is substantially smaller than that of I. Comments on ways to stabilize structures with desired small energy gaps are made. A correlation of the Eg with heteroatom perturbation and geometrical relaxation is given. The Eg is controlled not by aromatic vs. quinoid contributions, but by the geometrical and heteroat. effects on the frontier orbitals of the polymer.
 IT 115980-71-7
 RL: PRP (Properties)
 (band gap of)
 RN 115980-71-7 CAPLUS
 CN Poly(4,8-dihydropyrrolo[2,3,4,5-def]carbazole-1,2,3:5,6,7-hexayl) (9CI)
 (CA INDEX NAME)

L6 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



X



10/560,013

02/26/2007

L3 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1931:6290 CAPLUS
DOCUMENT NUMBER: 25:6290
ORIGINAL REFERENCE NO.: 25:716h-i
TITLE: 1-Aminocarbazole
INVENTOR(S): Muth, Friedrich; Schmelzer, Albert
PATENT ASSIGNEE(S): I. G. Farbenindustrie AG
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
	DE 507797		19270314	DE	
AB	1-Aminocarbazole and derivs. are prepared by first introducing the SO ₃ H group into the carbazole mol., then introducing the NO ₂ group into the 1-position, reducing it to the NH ₂ group, and finally removing the SO ₃ H group if desired. Examples describe the preparation of 1-nitrocarbazole-3,6,8-sulfonic acid, 1-aminocarbazole-3,6,8-sulfonic acid, 1-aminocarbazole and 1-phenylaminocarbazole.				
IT	859084-79-0P, Carbazole, 1-anilino-				
	RL: PREP (Preparation)				
	(preparation of)				
RN	859084-79-0 CAPLUS				
CN	INDEX NAME NOT YET ASSIGNED				

